

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
12 September 2002 (12.09.2002)

PCT

(10) International Publication Number
WO 02/070478 A1(51) International Patent Classification⁷: C07D 209/34,
A61K 31/404, A61P 35/00Claude [FR/FR]; Z.I. la Pompelle, Cedex 2, F-51689
Reims (FR).

(21) International Application Number: PCT/GB02/00947

(74) Agent: BRYANT, Tracey, et al; ASTRAZENECA,
Global Intellectual Property, Mereside, Alderley Park,
Macclesfield, Cheshire SK10 4TG (GB).

(22) International Filing Date: 4 March 2002 (04.03.2002)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
01400583.9 6 March 2001 (06.03.2001) EP(71) Applicant (for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE,
BF, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ,
DE, DK, DM, DZ, EC, EE, ES, FI, FR, GB, GD, GE, GH,
GM, GR, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KP,
KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MC, MD, MK,
MN, MW, MX, MZ, NL, NO, NZ, OM, PH, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, SZ, TJ, TM, TN, TR, TT, TZ, UA,
UG, UZ, VN, YU, ZA, ZM, ZW only): ASTRAZENECA
AB [SE/SE]; Sodertalje, S-151 85 (SE).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).(71) Applicant (for MG only): ASTRAZENECA UK LIM-
ITED [GB/GB]; 15 Stanhope Gate, London, Greater Lon-
don W1Y 6LN (GB).Published:
— with international search report

(72) Inventor; and

(75) Inventor/Applicant (for US only): ARNOULD, Jean,

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: INDOLONE DERIVATIVES HAVING VASCULAR-DAMAGING ACTIVITY

(57) Abstract: This invention relates to
the use of compounds of Formula (I) as
vascular damaging agents: wherein X
is selected from: -O-, -S-, -S(O)-, -S(O₂)-,
-N(R₅)-, -C(O)-, -C(O)N(R₅)-, -N(R₅)C(O)-,
-S(O₂)N(R₅)-, or -N(R₅)S(O₂)-; R₁ is
independently selected from: amino, halo,
hydroxy, -OPO₃H₂, C₁₋₄alkyl, or C₁₋₄alkoxy,
wherein the amino group is optionally
substituted by an amino acid residue and the
hydroxy group is optionally esterified; R₂is selected from: hydrogen or C₁₋₄alkyl; R₃ is selected from: hydrogen, halo, hydroxy, hydroxyC₁₋₄alkyl, cyano, cyanoC₁₋₄alkyl,
carboxy, carboxyC₁₋₄alkyl, C₁₋₄alkanoyl, C₁₋₄alkanoylC₁₋₄alkyl, carbamoyl, carbamoylC₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl,
C₁₋₄alkoxycarbonylC₁₋₄alkyl, C₁₋₄alkoxycarbonylamino, amino, N-C₁₋₄alkylamino, NN-diC₁₋₄alkylamino, aminoC₁₋₄alkyl,
N-C₁₋₄alkylaminoC₁₋₄alkyl, NN-diC₁₋₄alkylaminoC₁₋₄alkyl, ureido, or C₁₋₄alkylureleno; R₄ is independently selected from:
C₁₋₄alkyl, C₁₋₄alkoxy or halo; R₅ is selected from: hydrogen or C₁₋₄alkyl; n is 0 or 1; p is 0, 1, 2 or 3; and q is 0, 1 or 2; or a salt,
pro-drug or solvate thereof. The invention also relates to novel compounds of Formula (I) and to processes for the preparation of
compounds of Formula (I).

INDOLONE DERIVATIVES HAVING VASCULAR-DAMAGING ACTIVITY

This invention relates to vascular damaging agents and their uses. In particular it relates to certain novel compounds which may be of use as vascular damaging agents, to methods for preparing the compounds, to their use as medicaments (including in methods for
5 the treatment of angiogenesis or disease states associated with angiogenesis) and to pharmaceutical compositions containing them. The invention also relates to the use of such compounds, and of certain analogous, known compounds in the manufacture of medicaments for the production of anti-angiogenic and/or anti-vascular effects.

Normal angiogenesis plays an important role in a variety of processes including
10 embryonic development, wound healing and several components of female reproductive function. Undesirable or pathological angiogenesis has been associated with disease states including diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, atheroma, Kaposi's sarcoma and haemangioma (Fan et al, 1995, Trends Pharmacol. Sci. 16: 57-66; Folkman, 1995, Nature Medicine 1: 27-31). Formation of new vasculature by angiogenesis is a key
15 pathological feature of several diseases (J. Folkman, New England Journal of Medicine 333, 1757-1763 (1995)). For example, for a solid tumour to grow it must develop its own blood supply upon which it depends critically for the provision of oxygen and nutrients; if this blood supply is mechanically shut off the tumour undergoes necrotic death. Neovascularisation is also a clinical feature of skin lesions in psoriasis, of the invasive pannus in the joints of
20 rheumatoid arthritis patients and of atherosclerotic plaques. Retinal neovascularisation is pathological in macular degeneration and in diabetic retinopathy.

Reversal of neovascularisation by damaging the newly-formed vascular endothelium is therefore expected to have a beneficial therapeutic effect. Such vascular-damaging activity would clearly be of value in the treatment of disease states associated with angiogenesis such
25 as cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation, endometriosis, dysfunctional uterine bleeding and ocular diseases with retinal vessel proliferation.


Certain known compounds that cause selective destruction of tumour vasculature have
30 been reported, *in vitro* and at non-cytotoxic concentrations, to cause effects on proliferating endothelial cells, ie, cell detachment [Blakey D C et al, *Proceedings of the American*

- 2 -

Association for Cancer Research, 41, 329, 2000 abstract 2086] and changes in cell shape [Davis P D et al, *Proceedings of the American Association for Cancer Research*, 41, 329, 2000 abstract 2085; Chaplin D J & Dougherty G J, *Br J Cancer*, 80, Suppl 1, 57-64, 1999]. It can therefore be expected that these compounds will have damaging effects on newly-formed vasculature, for example the vasculature of tumours. It can reasonably be predicted, for example, that they will be capable of causing selective destruction of tumour vasculature, both *in vitro* and *in vivo*. Destruction of tumour vasculature in turn leads to a reduction in tumour blood flow and to tumour cell death due to starvation of oxygen and nutrients, ie, to anti-tumour activity [Davis P D et al; Chaplin D J & Dougherty G J; Blakey D C et al, all *supra*].

Compounds with this activity have also been described in International Patent Application WO 99/02166 (Angiogene Pharmaceuticals), International Patent Application WO00/40529 (Angiogene Pharmaceuticals) and International Patent Application WO 00/41669 (Angiogene Pharmaceuticals).

We have identified a novel class of compounds with vascular damaging activity. Thus, according to the first feature of the present invention there is provided the use of a compound of Formula (I) for the manufacture of a medicament to inhibit and/or reverse and/or alleviate symptom of angiogenesis and/or any disease state associated with angiogenesis, wherein:



Formula (I)

X is selected from: —O—, —S—, —S(O)—, —S(O₂)—, —N(R₅)—, —C(O)—, —C(O)N(R₅)—, —N(R₅)C(O)—, —S(O₂)N(R₅)—, or —N(R₅)S(O₂)—;

R₁ is independently selected from: amino, halo, hydroxy, —OPO₃H₂, C₁₋₄alkyl, or C₁₋₄alkoxy, wherein the amino group is optionally substituted by an amino acid residue and the hydroxy group is optionally esterified;

R₂ is selected from: hydrogen or C₁₋₄alkyl;

R₃ is selected from: hydrogen, halo, hydroxy, hydroxyC₁₋₄alkyl, cyano, cyanoC₁₋₄alkyl, carboxy, carboxyC₁₋₄alkyl, C₁₋₄alkanoyl, C₁₋₄alkanoylC₁₋₄alkyl, carbamoyl, carbamoylC₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, C₁₋₄alkoxycarbonylC₁₋₄alkyl, C₁₋₄alkoxycarbonylamino, amino,

- 3 -

N-C₁₋₄alkylamino, N,N-diC₁₋₄alkylamino, aminoC₁₋₄alkyl,
 N-C₁₋₄alkylaminoC₁₋₄alkyl, N,N-diC₁₋₄alkylaminoC₁₋₄alkyl, ureido, or
 C₁₋₄alkylureylene;

R₄ is independently selected from: C₁₋₄alkyl, C₁₋₄alkoxy or halo;

5 R₅ is selected from: hydrogen or C₁₋₄alkyl;

n is 0 or 1;

p is 0, 1, 2 or 3; and

q is 0, 1 or 2;

or a salt, pro-drug or solvate thereof.

10 Whilst pharmaceutically acceptable salts of compounds of the invention are preferred, other non-pharmaceutically acceptable salts of compounds of the invention may be useful in the preparation of pharmaceutically-acceptable salts of compounds of the invention.

According to a further aspect of the first feature of the invention there is provided a method of treatment, in a warm-blooded animal, to inhibit and/or reverse and/or alleviate
 15 symptom of angiogenesis and/or any disease state associated with angiogenesis comprising administering to said warm-blooded animal a therapeutically (including prophylactically) effective amount of a compound of Formula (I), or a salt, pro-drug or solvate thereof.

Preferably a warm-blooded animal is a human.

According to a further aspect of the first feature of the invention there is provided a
 20 pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically-acceptable salt, pro-drug or solvate thereof, in admixture with a pharmaceutically-acceptable diluent or carrier, to inhibit and/or reverse and/or alleviate symptom of angiogenesis and/or any disease state associated with angiogenesis.

For the avoidance of doubt when p is 0, all positions on the phenyl ring are substituted
 25 by hydrogen and when q is 0 all positions on the aromatic ring of the oxindole ring are substituted by hydrogen except for the position to which the '(R₁)_p-Phenyl-(CH₂)_n-X-' group is attached.

For the avoidance of doubt the use of the term (R₁)_p when p is between 1 and 3, means that there are 1, 2 or 3 R¹ substituents on the phenyl ring, which when p is 2 or 3 can be the
 30 same group or different groups. For example, where (R₁)_p is 3-chloro-4-methoxy then p is 2 and the phenyl ring has a chloro group at the 3-position and a methoxy group at the 4-position, in relation to the —(CH₂)_nX— group, and for example, when (R₁)_p is di-halo, then p is 2 and

- 4 -


the phenyl ring has two halo substituents which may be the same group or different groups, wherein the halo groups occupy 2 positions on the phenyl ring.

In this specification the generic term 'alkyl' includes both straight-chain and branched-chain alkyl groups. However references to individual alkyl groups such as 'propyl' are specific for the straight-chain version only and references to individual branched-chain alkyl groups such as 'isopropyl' are specific for the branched-chain version only. An analogous convention applies to other generic terms.

The term **halo** refers to fluoro, chloro, bromo or iodo.

The term **carbamoyl** refers to $-C(O)NH_2$.

10 An amino acid residue is defined as that derived from the coupling of an L-amino acid with an amino group via an amide bond. This bond can either be formed via a carboxylate group on the amino acid backbone or via a side chain carboxylate group, preferably via carboxylate group on the amino acid backbone. Amino acid residues include those derived from natural and non-natural amino acids, preferably natural amino acids and include α -amino acids, β -amino acids and γ -amino acids. For the avoidance of doubt amino acids include those with the generic structure:



where R is the amino acid side chain: The definition of amino acid also includes amino acid analogues which have additional methylene groups within the amino acid backbone, for example β -alanine.

Preferred amino acids include glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tryptophan, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, β -alanine and ornithine. More preferred amino acids include glutamic acid, serine, threonine, arginine, glycine, alanine, β -alanine and lysine. Especially preferred amino acids include glutamic acid, serine, and glycine.

Preferably esterifying groups at R_1 are esterifying groups which increase the solubility of the molecule in water at a pH of approximately pH=7. Such groups included groups with ionisable groups, such as acidic functions or basic functions and groups containing a

- 5 -

hydrophilic function. Basic functions include: amino, morpholino, piperidino, piperazino, pyrrolidino, amino acids and imidazolino. Acidic functions include: carboxy, sulphonic acid, phosphate, sulphate and acid mimetics such as tetrazolyl. Hydrophilic groups include hydroxyl.

- 5 Preferred R₁ groups wherein hydroxy is esterified include: C₁₋₆alkanoyloxy, arylcarbonyloxy, heterocyclylcarbonyloxy, heteroarylcarbonyloxy wherein the R₁ group is optionally substituted with between 1 and 3 groups selected from C₁₋₄alkyl, C₁₋₄alkanoyl, C₁₋₄alkanoylC₁₋₄alkyl, C₁₋₄alkanoylheterocyclyl, hydroxy, hydroxyC₁₋₄alkyl, carboxy, carboxyphenyl, phosphono, phosphonoC₁₋₄alkyl, amino, aminoC₁₋₄alkyl, N-C₁₋₄alkylamino, N,N-diC₁₋₄alkylamino, carbamoyl, carbamoylC₁₋₄alkyl, heterocyclyl, heterocyclylC₁₋₄alkyl, heterocyclylcarbonyl, heterocyclC₁₋₄alkanoylamino, carbamoylheterocyclyl, [wherein optional substituents comprising heterocyclyl are optionally further substituted by C₁₋₄alkyl, hydroxyC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkanoyl and formyl, wherein the carbamoyl and amino optional substituents are optionally further N-substituted by, C₁₋₄alkyl, di-C₁₋₄alkyl, hydroxyC₁₋₄alkyl, di-(hydroxyC₁₋₄alkyl), carboxyC₁₋₄alkyl, and wherein the amino group is optionally substituted by an amino acid residue] with the proviso that when R₁ is C₁₋₆alkanoyloxy or arylcarbonyloxy R₁ is not unsubstituted and R₁ is not substituted by C₁₋₄alkyl.

- More preferred R₁ groups wherein hydroxy is esterified include: carboxypentanoyloxy, 4-carboxyphenylpropanoyloxy 4-(N-methylpiperizin-1-ylethyl)phenylcarbonyloxy, 4-(piperizin-1-ylethyl)phenylcarbonyloxy, 4-[N-di-(hydroxyethyl)aminomethyl]phenylcarbonyloxy, 3-(N-acetyl piperizin-1-ylethyl)phenylcarbonyloxy, 3-[N-di-(hydroxyethyl)aminomethyl]phenylcarbonyloxy, 4-(N-methylpiperizin-1-ylpropanoylamino)phenylcarbonyloxy, N-methylpiperizin-1-ylcarbonylpropanoyloxy, N-di-(hydroxyethyl)aminocarbonylpropanoyloxy, piperizin-1-ylcarbonylpropanoyloxy, (N-acetyl piperizin-1-yl)carbonylpropanoyloxy, (N-di-(hydroxyethyl)aminocarbonylpropanoyloxy, and 4-(piperizin-1-ylmethyl)phenylcarbonyloxy.

- 30 Further preferred R₁ groups wherein hydroxy is esterified include: 4-(N-methylpiperizin-1-ylpropanoylamino)phenylcarbonyloxy, N-methylpiperizin-1-ylcarbonylpropanoyloxy and N-di-(hydroxyethyl)aminocarbonylpropanoyloxy.

- 6 -

Examples of **C₁₋₄alkyl** include methyl, ethyl, propyl, isopropyl, *sec*-butyl and *tert*-butyl, examples of **hydroxyC₁₋₄alkyl** include hydroxymethyl, hydroxyethyl and hydroxypropyl, examples of **aminoC₁₋₄alkyl** include aminomethyl, aminoethyl or aminopropyl, examples of **cyanoC₁₋₄alkyl** include cyanomethyl, cyanoethyl and cyanopropyl, examples of **carboxyC₁₋₄alkyl** include carboxymethyl, carboxyethyl or carboxypropyl, examples of **carbamoylC₁₋₄alkyl** include aminocarbonylmethyl, aminocarbonylethyl and aminocarbonypropyl, examples of **C₁₋₄alkoxy** include methoxy, ethoxy and propoxy, examples of **C₁₋₄alkoxycarbonyl** include methoxycarbonyl, *tert*-butoxycarbonyl, ethoxycarbonyl and propoxycarbonyl, examples of **C₁₋₄alkoxycarbonylC₁₋₄alkyl** include methoxycarbonylmethyl, *tert*-butoxycarbonylethyl, ethoxycarbonylmethyl and propoxycarbonylethyl, examples of **C₁₋₄alkoxycarbonylamino** include methoxycarbonylamino and *t*-butoxycarbonylamino, examples of **C₁₋₄alkanoyl** include acetyl, ethylcarbonyl and butylcarbonyl, examples of **N-C₁₋₄alkylamino** include N-methylamino and N-ethylamino, and examples of **N,N-diC₁₋₄alkylamino** include N,N-dimethylamino, N,N-diethylamino and N-methyl-N-ethylamino, examples of **N-C₁₋₄alkylaminoC₁₋₄alkyl** include *N*-methylaminomethyl and *N*-ethylaminoethyl, examples of **N,N-di-C₁₋₄alkylaminoC₁₋₄alkyl** include *N,N*-dimethylaminomethyl and *N*-methyl-*N*-ethylaminomethyl, examples of **C₁₋₄alkylureyleno** include methylureyleno, ethylureyleno or propylureyleno.

A suitable pharmaceutically-acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically-acceptable salt of a carbazole derivative of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

The compounds of the Formula (I) may be administered in the form of a pro-drug which is broken down in the human or animal body to give a compound of the Formula (I). Examples of pro-drugs include in-vivo hydrolysable esters of a compound of the Formula (I).

- 7 -

Various forms of prodrugs are known in the art. For examples of such prodrug derivatives, see:

- a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, *et al.* (Academic Press, 1985);
- 5 b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs", by H. Bundgaard p. 113-191 (1991);
- c) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992);
- d) H. Bundgaard, *et al.*, Journal of Pharmaceutical Sciences, 77, 285 (1988); and
- 10 e) N. Kakeya, *et al.*, Chem Pharm Bull, 32, 692 (1984).

An in-vivo hydrolysable ester of a compound of the Formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically-acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically-acceptable esters for carboxy include C₁₋₆alkoxymethyl esters for example methoxymethyl, 15 C₁₋₆alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C₃₋₈cycloalkoxycarbonyloxyC₁₋₆alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters, for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C₁₋₆alkoxycarbonyloxyethyl esters.

An in-vivo hydrolysable ester of a compound of the Formula (I) containing a 20 hydroxy group includes inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and α -acyloxyalkyl ethers and related compounds which as a result of the in-vivo hydrolysis of the ester breakdown to give the parent hydroxy group/s. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy. A selection of in-vivo hydrolysable ester forming groups for hydroxy include alkanoyl, 25 benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl.

It is to be understood that, insofar as certain of the compounds in the different features of the invention may exist in optically active or racemic forms by virtue of one or more 30 asymmetric carbon atoms, the invention includes in its definition any such optically active or racemic form which possesses the property of inhibiting and/or reversing and/or alleviating the symptoms of angiogenesis and/or any disease states associated with angiogenesis. The


- 8 -

synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form. Similarly, activity of these compounds may be evaluated using the standard laboratory techniques referred to hereinafter.

- 5 The invention also relates to any and all tautomeric forms of the compounds of the different features of the invention that possess the property of inhibiting and/or reversing and/or alleviating the symptoms of angiogenesis and/or any disease states associated with angiogenesis.

It will also be understood that certain compounds of the present invention may exist in
10 solvated, for example hydrated, as well as unsolvated forms. It is to be understood that the present invention encompasses all such solvated forms which possess the property of the property of inhibiting and/or reversing and/or alleviating the symptoms of angiogenesis and/or any disease states associated with angiogenesis.

According to a second feature of the invention there is provided the use of a
15 compound of Formula (II) as a medicament:



Formula (II)

X is selected from: —O—, —S—, —S(O)—, —S(O₂)—, —N(R₅)—, —C(O)—, —C(O)N(R₅)—, —N(R₅)C(O)—, —S(O₂)N(R₅)—, or —N(R₅)S(O₂)—;

- 20 R₁ is independently selected from: amino, halo, hydroxy, —OPO₃H₂, C₁₋₄alkyl, or C₁₋₄alkoxy, wherein the amino group is optionally substituted by an amino acid residue and the hydroxy group is optionally esterified;

R₂ is selected from: hydrogen or C₁₋₄alkyl;

- R₃ is selected from: hydrogen, halo, hydroxy, hydroxyC₁₋₄alkyl, cyano, cyanoC₁₋₄alkyl,
25 carboxy, carboxyC₁₋₄alkyl, C₁₋₄alkanoyl, C₁₋₄alkanoylC₁₋₄alkyl, carbamoyl, carbamoylC₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, C₁₋₄alkoxycarbonylC₁₋₄alkyl, C₁₋₄alkoxycarbonylamino, amino, N-C₁₋₄alkylamino, NN-diC₁₋₄alkylamino, aminoC₁₋₄alkyl,

- 9 -

N-C₁₋₄alkylaminoC₁₋₄alkyl, NN-diC₁₋₄alkylaminoC₁₋₄alkyl, ureido, or C₁₋₄alkylureylene;

R₄ is independently selected from: C₁₋₄alkyl, C₁₋₄alkoxy or halo;

R₅ is selected from: hydrogen or C₁₋₄alkyl;

5 n is 0 or 1;

p is 1, 2 or 3; and

q is 0, 1 or 2;


with the proviso that:

(i) when p is 1, R₁ cannot be halo or methyl, and when p is 2, (R₁)_p cannot be di-halo or
10 di-methyl;

(ii) when X is —S(O₂)N(R₅)—, —N(R₅)S(O₂)—, —N(R₅)C(O)— or —C(O)—, n is 0 or 1, R₂ is hydrogen, R₃ is hydrogen, q is 0 or q is 1 and R₄ is 5-chloro and R⁵ is hydrogen, then (R₁)_p cannot be 2-methoxy, 3-methoxy, 4-methoxy, 4-nitro, 4-hydroxy, 4-amino, 3-chloro-4-methoxy or 3-chloro-4-ethoxy; and

15 (ii) when X is linked at the 7-position of the oxindole ring, X is —O—, n is 0, R₂ is hydrogen, R₃ is hydrogen or methyl and q is 0, then (R₁)_p cannot be 2-methoxy, 2-amino, or 3,4,5-tri-methoxy; or a pharmaceutically-acceptable salt, pro-drug or solvate thereof.

According to a further aspect of the second feature of the invention there is provided a compound of Formula (IIa):



20

Formula (IIa)

wherein X, R¹, R², R³, R⁴, R⁵, n, p and q are as defined for a compound of Formula (II);
with the proviso that:

(i) when p is 1, R₁ cannot be halo or methyl, and when p is 2, (R₁)_p cannot be di-halo or
25 di-methyl;

(ii) when X is —S(O₂)N(R₅)—, —N(R₅)S(O₂)—, —N(R₅)C(O)— or —C(O)—, n is 0 or 1, R₂ is hydrogen, R₃ is hydrogen, q is 0 or q is 1 and R₄ is 5-chloro and R⁵ is hydrogen, then (R₁)_p cannot be 2-methoxy, 3-methoxy, 4-methoxy, 4-nitro, 4-hydroxy, 4-amino, 3-chloro-4-methoxy or 3-chloro-4-ethoxy; and

- 10 -


(ii) when X is linked at the 7-position of the oxindole ring, X is —O—, n is 0, R₂ is hydrogen, R₃ is hydrogen or methyl and q is 0, then (R₁)_p cannot be 2-methoxy, 2-amino, or 3,4,5-tri-methoxy;

or a pharmaceutically-acceptable salt, pro-drug or solvate thereof.

5 According to a further aspect of the second feature of the invention there is provided a pharmaceutical composition comprising a compound of Formula (II) or Formula (IIa), or pharmaceutically-acceptable salt, pro-drug or solvate.

According to a further aspect of the second feature of the invention there is provided a pharmaceutical composition comprising a compound of Formula (II) or Formula (IIa), or a
10 pharmaceutically-acceptable salt, pro-drug or solvate thereof, in admixture with a pharmaceutically-acceptable diluent or carrier.

According to a third feature of the invention there is provided a compound of Formula (III), wherein:



15 Formula (III)

X is selected from: —S—, —S(O)—, or —S(O₂)—;

R₁ is independently selected from: amino, halo, hydroxy, —OPO₃H₂, C₁₋₄alkyl, or C₁₋₄alkoxy, wherein the amino group is optionally substituted by an amino acid residue and the hydroxy group is optionally esterified;

20 R₂ is selected from: hydrogen or C₁₋₄alkyl;

R₃ is selected from: hydrogen; halo, hydroxy, hydroxyC₁₋₄alkyl, cyano, cyanoC₁₋₄alkyl, carboxy, carboxyC₁₋₄alkyl, C₁₋₄alkanoyl, C₁₋₄alkanoylC₁₋₄alkyl, carbamoyl, carbamoylC₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, C₁₋₄alkoxycarbonylC₁₋₄alkyl, C₁₋₄alkoxycarbonylamino, amino,
25 N-C₁₋₄alkylamino, NN-diC₁₋₄alkylamino, aminoC₁₋₄alkyl, N-C₁₋₄alkylaminoC₁₋₄alkyl, NN-diC₁₋₄alkylaminoC₁₋₄alkyl, ureido, or C₁₋₄alkylureyleno;

R₄ is independently selected from: C₁₋₄alkyl, C₁₋₄alkoxy or halo;

n is 0 or 1;

- 11 -

p is 0, 1, 2 or 3; and

q is 0, 1 or 2;

with the proviso that the following compounds are excluded:

- 7-(phenylsulfanyl)-1,3-dihydro-2*H*-indol-2-one;
- 5 7-(2-chlorophenylsulfanyl)-1,3-dihydro-2*H*-indol-2-one;
- 7-(4-chlorophenylsulfanyl)-1,3-dihydro-2*H*-indol-2-one;
- 7-(benzylsulfanyl)-1,3-dihydro-2*H*-indol-2-one;
- 7-(phenylsulfinyl)-1,3-dihydro-2*H*-indol-2-one;
- 7-(2-chlorophenylsulfinyl)-1,3-dihydro-2*H*-indol-2-one;
- 10 7-(4-chlorophenylsulfinyl)-1,3-dihydro-2*H*-indol-2-one;
- 7-(phenylsulfonyl)-1,3-dihydro-2*H*-indol-2-one; and
- 7-(4-chlorophenylsulfonyl)-1,3-dihydro-2*H*-indol-2-one;

or pharmaceutically-acceptable salt, pro-drug or solvate thereof.


According to a further aspect of the third feature of the invention there is provided a
15 compound of Formula (III); as defined above,

with the proviso that:

when $-(CH_2)_nX-$ is linked at the 7-position of the oxindole ring, n is 0 or 1, R_2 and R_3 are each independently hydrogen and q is 0, then p cannot be 0 and $(R_1)_p$ cannot be 2-chloro or 4-chloro;

20 or pharmaceutically-acceptable salt, pro-drug or solvate thereof.

According to a fourth feature of the invention there is provided a compound of Formula (IV), wherein:



Formula (IV)

25 R_1 is independently selected from: amino, halo, hydroxy, $-OPO_3H_2$, C_{1-4} alkyl, or C_{1-4} alkoxy, wherein the amino group is optionally substituted by an amino acid residue and the hydroxy group is optionally esterified;

R_2 is selected from: hydrogen or C_{1-4} alkyl;

- 12 -

R₃ is selected from: hydrogen, halo, hydroxy, hydroxyC₁₋₄alkyl, cyano, cyanoC₁₋₄alkyl, carboxy, carboxyC₁₋₄alkyl, C₁₋₄alkanoyl, C₁₋₄alkanoylC₁₋₄alkyl, carbamoyl, carbamoylC₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, C₁₋₄alkoxycarbonylC₁₋₄alkyl, C₁₋₄alkoxycarbonylamino, amino, N-C₁₋₄alkylamino, NN-diC₁₋₄alkylamino, aminoC₁₋₄alkyl, N-C₁₋₄alkylaminoC₁₋₄alkyl, NN-diC₁₋₄alkylaminoC₁₋₄alkyl, ureido, or C₁₋₄alkylureyleno;

R₄ is independently selected from: C₁₋₄alkyl, C₁₋₄alkoxy or halo;

R₅ is selected from: hydrogen or C₁₋₄alkyl;

n is 0 or 1;

p is 0, 1, 2 or 3; and

q is 0, 1 or 2;

with the proviso that the following compounds are excluded:

5-(benzylamino)-1,3-dihydro-2*H*-indol-2-one;

7-anilino-1,3-dihydro-2*H*-indol-2-one;

7-(2-chloroanilino)-1,3-dihydro-2*H*-indol-2-one; and

7-(4-chloroanilino)-1,3-dihydro-2*H*-indol-2-one;

or pharmaceutically-acceptable salt, pro-drug or solvate thereof.

According to a further aspect of the fourth feature of the invention there is provided a compound of Formula (IV), as defined above,

with the proviso that:


(i) when $-(CH_2)_nN(R_5)-$ is linked at the 5-position of the oxindole ring, n is 1, R₂ and R₃ are each independently hydrogen and q is 0, then p cannot be 0; and

(ii) when $-(CH_2)_nN(R_5)-$ is linked at the 7-position of the oxindole ring, n is 0, R₂ and R₃ are each independently hydrogen and q is 0, then p cannot be 0 and (R₁)_p cannot be 2-chloro or 4-chloro;

or pharmaceutically-acceptable salt, pro-drug or solvate thereof.

According to a fifth feature of the invention there is provided a compound of Formula (V), wherein:

- 13 -



Formula (V)

R_1 is independently selected from: amino, halo, hydroxy, $-OPO_3H_2$, C_{1-4} alkyl, or C_{1-4} alkoxy, wherein the amino group is optionally substituted by an amino acid residue and the hydroxy group is optionally esterified;

R_2 is selected from: hydrogen or C_{1-4} alkyl;

R_3 is selected from: hydrogen, halo, hydroxy, hydroxy C_{1-4} alkyl, cyano, cyano C_{1-4} alkyl, carboxy, carboxy C_{1-4} alkyl, C_{1-4} alkanoyl, C_{1-4} alkanoyl C_{1-4} alkyl, carbamoyl, carbamoyl C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkoxycarbonyl, C_{1-4} alkoxycarbonyl C_{1-4} alkyl, C_{1-4} alkoxycarbonylamino, amino, N- C_{1-4} alkylamino, NN-di C_{1-4} alkylamino, amino C_{1-4} alkyl, N- C_{1-4} alkylamino C_{1-4} alkyl, NN-di C_{1-4} alkylamino C_{1-4} alkyl, ureido, or C_{1-4} alkylureyleno;

R_4 is independently selected from: C_{1-4} alkyl, C_{1-4} alkoxy or halo;

R_5 is selected from: hydrogen or C_{1-4} alkyl;

n is 0 or 1;

p is 0, 1, 2 or 3; and

q is 0, 1 or 2;


with the proviso that:

- (i) when $-(CH_2)_nO-$ is linked at the 4-position of the oxindole ring, n is 0, p is 0 and R_2 and R_3 are each independently hydrogen and q is 1 then R_4 cannot be 7-chloro;
- (ii) when $-(CH_2)_nO-$ is linked at the 5-position of the oxindole ring, n is 0 or 1, R_2 is hydrogen or methyl, R_3 is hydrogen and q is 0, then p cannot be 0 and $(R_1)_p$ cannot be 2-chloro or 4-chloro;
- (iii) when $-(CH_2)_nO-$ is linked at the 6-position of the oxindole ring, n is 1, p is 0, R_2 is hydrogen or methyl, R_3 is hydrogen and q is 1 then R_4 cannot be 5-methoxy; and
- (iv) when $-(CH_2)_nO-$ is linked at the 7-position of the oxindole ring, n is 0 or 1, R_2 is hydrogen or methyl, R_3 is hydrogen and q is 0, then p cannot be 0 and $(R_1)_p$ cannot be 2-chloro, 2-fluoro, 2-amino, 2,6-dichloro or 3,4,5-trimethoxy;

- 14 -

or pharmaceutically-acceptable salt, pro-drug or solvate thereof.

According to the sixth feature of the invention there is provided a compound of Formula (VI), wherein:



5

Formula (VI)

R_1 is independently selected from: amino, halo, hydroxy, $-OPO_3H_2$, C_{1-4} alkyl, or C_{1-4} alkoxy, wherein the amino group is optionally substituted by an amino acid residue and the hydroxy group is optionally esterified;

R_2 is selected from: hydrogen or C_{1-4} alkyl;

10 R_3 is selected from: hydrogen, halo, hydroxy, hydroxy C_{1-4} alkyl, cyano, cyano C_{1-4} alkyl, carboxy, carboxy C_{1-4} alkyl, C_{1-4} alkanoyl, C_{1-4} alkanoyl C_{1-4} alkyl, carbamoyl, carbamoyl C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkoxycarbonyl, C_{1-4} alkoxycarbonyl C_{1-4} alkyl, C_{1-4} alkoxycarbonylamino, amino, N- C_{1-4} alkylamino, NN-di C_{1-4} alkylamino, amino C_{1-4} alkyl, 15 N- C_{1-4} alkylamino C_{1-4} alkyl, NN-di C_{1-4} alkylamino C_{1-4} alkyl, ureido, or C_{1-4} alkylureyleno;

R_4 is independently selected from: C_{1-4} alkyl, C_{1-4} alkoxy or halo;

R_5 is selected from: hydrogen or C_{1-4} alkyl;

n is 0 or 1;

20 p is 0, 1, 2 or 3; and

q is 0, 1 or 2;

with the proviso that:


(i) when $-(CH_2)_nC(O)-$ is linked at the 4-position of the oxindole ring, n is 0, p is 0, R_2 and R_3 are each independently hydrogen, then q cannot be 0;

25 (ii) when $-(CH_2)_nC(O)-$ is linked at the 5-position of the oxindole ring, n is 0, R_2 is hydrogen or ethyl, R_3 is hydrogen or methoxycarbonyl and q is 0, then p cannot be 0 and $(R_1)_p$ cannot be 4-methyl, 4-chloro or 4-fluoro;

- 15 -

- (iii) when $-(CH_2)_nC(O)-$ is linked at the 6-position of the oxindole ring, n is 0, R_2 is hydrogen or ethyl, R_3 is hydrogen and q is 0, then p cannot be 0 and $(R_1)_p$ cannot be 4-methyl, 4-methoxy or 4-chloro;
- (iv) when $-(CH_2)_nC(O)-$ is linked at the 7-position of the oxindole ring, n is 0, R_2 is hydrogen, methyl or ethyl, R_3 is hydrogen, hydroxy, methoxycarbonyl, or ethoxycarbonyl, and q is 0 or q is 1 and R_4 is 4-methyl, 5-methyl, 6-methyl, 5-methoxy, 5-chloro, 6-chloro, 5-bromo or 5-fluoro, then p cannot be 0 and $(R_1)_p$ cannot be 2-methyl, 4-methyl, 4-methoxy, 4-hydroxy, 4-chloro, 4-bromo, 2-fluoro, 4-fluoro, 4-iodo, 2,4-dimethyl, 2,4-dichloro, 3,4-dichloro or 2-chloro-4-bromo;
- 10 or a salt, pro-drug or solvate thereof.

According to the seventh feature of the invention there is provided a compound of Formula (VII), wherein:



Formula (VII)

- 15 X is selected from: $-C(O)N(R_5)-$ or $-N(R_5)C(O)-$;
- R_1 is independently selected from: amino, halo, hydroxy, $-OPO_3H_2$, C_{1-4} alkyl, or C_{1-4} alkoxy, wherein the amino group is optionally substituted by an amino acid residue and the hydroxy group is optionally esterified;
- R_2 is selected from: hydrogen or C_{1-4} alkyl;
- 20 R_3 is selected from: hydrogen, halo, hydroxy, hydroxy C_{1-4} alkyl, cyano, cyano C_{1-4} alkyl, carboxy, carboxy C_{1-4} alkyl, C_{1-4} alkanoyl, C_{1-4} alkanoyl C_{1-4} alkyl, carbamoyl, carbamoyl C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkoxycarbonyl, C_{1-4} alkoxycarbonyl C_{1-4} alkyl, C_{1-4} alkoxycarbonylamino, amino, N- C_{1-4} alkylamino, NN-di C_{1-4} alkylamino, amino C_{1-4} alkyl,
- 25 N- C_{1-4} alkylamino C_{1-4} alkyl, NN-di C_{1-4} alkylamino C_{1-4} alkyl, ureido, or C_{1-4} alkylureyleno;
- R_4 is independently selected from: C_{1-4} alkyl, C_{1-4} alkoxy or halo;
- R_5 is selected from: hydrogen or C_{1-4} alkyl;
- n is 0 or 1;

- 16 -


p is 0, 1, 2 or 3; and

q is 0, 1 or 2;

with the proviso that:

- (i) when X is $\text{—N(R}_5\text{)}_n\text{C(O)—}$ linked at the 4-position of the oxindole ring, n is 0, R_2 , R_3 and R_5 are each independently hydrogen and q is 0, then $(\text{R}_1)_p$ cannot be 4-methoxy, 3-chloro-4-methoxy or 3-chloro-4-ethoxy; and
- (ii) when X is $\text{—C(O)N(R}_5\text{)}_n\text{—}$ linked at the 5-position of the oxindole ring, n is 0, p is 0, R_2 , R_3 and R_5 are each independently hydrogen, then q cannot be 0 or a salt, pro-drug or solvate thereof.

According to the eight feature of the invention there is provided a compound of Formula (VIII), wherein:



Formula (VIII)

X is selected from: $\text{—S(O}_2\text{)N(R}_5\text{)—}$ or $\text{—N(R}_5\text{)S(O}_2\text{)—}$;

- R_1 is independently selected from: amino, halo, hydroxy, $\text{—OPO}_3\text{H}_2$, C_{1-4} alkyl, or C_{1-4} alkoxy, wherein the amino group is optionally substituted by an amino acid residue and the hydroxy group is optionally esterified;

R_2 is selected from: hydrogen or C_{1-4} alkyl;

- R_3 is selected from: hydrogen, halo, hydroxy, hydroxy C_{1-4} alkyl, cyano, cyano C_{1-4} alkyl, carboxy, carboxy C_{1-4} alkyl, C_{1-4} alkanoyl, C_{1-4} alkanoyl C_{1-4} alkyl, carbamoyl, carbamoyl C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkoxycarbonyl, C_{1-4} alkoxycarbonyl C_{1-4} alkyl, C_{1-4} alkoxycarbonylamino, amino, N-C_{1-4} alkylamino, NN-diC_{1-4} alkylamino, amino C_{1-4} alkyl, N-C_{1-4} alkylamino C_{1-4} alkyl, NN-diC_{1-4} alkylamino C_{1-4} alkyl, ureido, or C_{1-4} alkylureylene;

R_4 is independently selected from: C_{1-4} alkyl, C_{1-4} alkoxy or halo;

R_5 is selected from: hydrogen or C_{1-4} alkyl;

n is 0 or 1;

p is 0, 1, 2 or 3; and

q is 0,1 or 2;

with the proviso that the following compounds are excluded:

- 4-(4-methylbenzenesulphonamido)-1,3-dihydro-2*H*-indol-2-one;
- 5-benzenesulphonamido-1,3-dihydro-2*H*-indol-2-one;
- 5-(4-methylbenzenesulphonamido)-1,3-dihydro-2*H*-indol-2-one;
- N-methyl-5-(4-methylbenzenesulphonamido)-1,3-dihydro-2*H*-indol-2-one;
- N-methyl-5-(N-methyl-4-methylbenzenesulphonamido)-1,3-dihydro-2*H*-indol-2-one;
- 6-(4-methylbenzenesulphonamido)-1,3-dihydro-2*H*-indol-2-one;
- 6-(N-methyl-4-methylbenzenesulphonamido)-1,3-dihydro-2*H*-indol-2-one;
- 7-(4-methylbenzenesulphonamido)-1,3-dihydro-2*H*-indol-2-one ;
- 6-(4-methoxybenzenesulphonamido)-1,3-dihydro-2*H*-indol-2-one;
- 6-(4-aminobenzenesulphonamido)-1,3-dihydro-2*H*-indol-2-one; and
- 6-(4-chlorobenzenesulphonamido)-1,3-dihydro-2*H*-indol-2-one;

or a salt pro-drug or solvate thereof.

According to a further aspect of the eighth feature of the invention there is provided a compound of Formula (VIII), as defined above,

with the proviso that:

- (i) when X is —S(O₂)N(R₅)— linked at the 4 position of the oxindole ring, n is 0, R₂ and R₃ are each independently hydrogen, q is 0, and R₅ is hydrogen, then (R₁)_p cannot be 4-methyl;
- (ii) when X is —S(O₂)N(R₅)— linked at the 5 position of the oxindole ring, n is 0, R₂ is hydrogen or methyl, R₃ is hydrogen, q is 0 and R₅ is hydrogen or methyl, then (R₁)_p cannot be 4-methyl;
- (iii) when X is —N(R₅)S(O₂)— linked at the 5-position of the oxindole ring, n is 0 or 1, R² and R³ are each independently hydrogen, q is 0 and R⁵ is hydrogen, methyl or ethyl, then p cannot be 0 and (R₁)_p cannot be 3-methyl, 2-methoxy, 3-methoxy, 3 chloro, 4-fluoro, or 2-fluoro—4-chloro.
- (iv) when X is —S(O₂)N(R₅)— linked at the 6 position of the oxindole ring, n is 0, R₂ and R₃ are each independently hydrogen, q is 0 and R₅ is hydrogen or methyl, then (R₁)_p cannot be 4-methyl; and

- 18 -

(v) when X is $\text{—S(O}_2\text{)N(R}_5\text{)—}$ linked at the 7 position of the oxindole ring, n is 0, R₂ is hydrogen or methyl, R₃ is hydrogen, q is 0 and R₅ is hydrogen, then (R₁)_p cannot be 4-methyl, 4-methoxy, 4-amino or 4-chloro;

or a salt, pro-drug or solvate thereof.

5 According to a further aspect of the third, fourth, fifth, sixth, seventh or eighth feature of the invention there is provided the use of a compound of Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII) or Formula (VIII) respectively, or pharmaceutically-acceptable salt, pro-drug or solvate thereof in the manufacture of a medicament to inhibit and/or reverse and/or alleviate symptom of angiogenesis and/or any
10 disease state associated with angiogenesis, in a warm blooded animal.

According to a further aspect of the third, fourth, fifth, sixth, seventh or eighth feature of the invention there is provided a pharmaceutical composition comprising a compound of Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII) or Formula (VIII) respectively, or a pharmaceutically-acceptable salt, pro-drug or solvate
15 thereof, in admixture with a pharmaceutically-acceptable diluent or carrier for the treatment of a warm-blooded animal, to inhibit and/or reverse and/or alleviate symptom of angiogenesis and/or any disease state associated with angiogenesis.

A preferred group of values of X in each feature of the invention is —O— , —S— , —S(O)— , $\text{—S(O}_2\text{)—}$, or $\text{—N(R}_5\text{)—}$. Preferably X is —O— , —S— or $\text{—N(R}_5\text{)—}$. Most
20 preferably X is —O— or —S— .

Preferably when n is 0, X is linked at the 5-position of the indole ring.

Preferably when n is 1, X is linked at the 6-position of the indole ring.

A preferred group of values of R₁ in each feature of the invention is hydrogen, amino, hydroxy, methyl or methoxy wherein the amino group is optionally substituted by an amino
25 acid and the hydroxy group is optionally esterified. Preferably R₁ is hydrogen, amino, hydroxy, glutaminylamino, serylalmino, alanylalmino, glycylalmino or $\text{—PO}_3\text{H}_2$, wherein the hydroxy group is optionally esterified. More preferably R₁ is hydrogen, amino, hydroxy, glutaminylamino, serylalmino, glycylalmino or $\text{—PO}_3\text{H}_2$.

A preferred group of values of R₂ in each feature of the invention is hydrogen, methyl
30 or ethyl; Preferably R₂ is hydrogen or methyl.

A preferred group of values of R₃ in each feature of the invention is hydrogen, carbamoyl, or C₁₋₄alkylcarbamoyl. Preferably R₃ is hydrogen.

- 19 -

A preferred group of values of R_4 in each feature of the invention is hydrogen or C_{1-4} alkyl. Preferably hydrogen.

A preferred group of compound of each feature of the invention described herein; comprise compounds wherein:

5 X is —O—.

A further preferred group of compound of each feature of the invention described herein; comprise compounds wherein:

X is —N—.

A further preferred group of compound of each feature of the invention described
10 herein; comprise compounds wherein:

X is —S—, —S(O)— or —S(O₂)—, preferably —S—.

A further preferred group of compound of each feature of the invention described herein; comprise compounds wherein:

R_1 is amino, hydroxy or —OPO₃H₂, wherein the amino group is optionally substituted by
15 an amino acid residue and the hydroxy group is optionally esterified.

A further preferred group of compound of each feature of the invention described herein; comprise compounds wherein:

R_1 is amino, hydroxy or —OPO₃H₂, wherein the amino group is optionally substituted by an amino acid residue and the hydroxy group is optionally esterified; and

20 R_3 is carbamoyl, or C_{1-4} alkylcarbamoyl.

Particular compounds of each feature of the invention are:

5-(phenylsulfanyl)-1,3-dihydro-2*H*-indol-2-one ;

5-(4-aminophenoxy)-1,3-dihydro-2*H*-indol-2-one ;

5-(4-aminophenylsulfanyl)-1,3-dihydro-2*H*-indol-2-one;

25 5-(4-hydroxyphenylsulfanyl)-1,3-dihydro-2*H*-indol-2-one; and

6-(3-aminobenzyloxy)-1,3-dihydro-2*H*-indol-2-one;

or a salt, pro-drug or solvate thereof

More particular compounds of each feature of the invention are:

5-(4-N-glutaminylaminophenoxy)-1,3-dihydro-2*H*-indol-2-one;

30 5-(4-N-Serylaminophenoxy)-1,3-dihydro-2*H*-indol-2-one;

5-(4-N-Glycylaminophenoxy)-1,3-dihydro-2*H*-indol-2-one;

5-(4-N-glutaminylaminophenylsulfanyl)-1,3-dihydro-2*H*-indol-2-one;

5-(3-N-glutaminylaminobenzyloxy)-1,3-dihydro-2*H*-indol-2-one; and


- 20 -

5-(4-phosphonophenylsulfanyl)-1,3-dihydro-2*H*-indol-2-one
or a salt, pro-drug or solvate thereof.


A compound of the invention or a pharmaceutically-acceptable salt, or solvate thereof, may be prepared by any process known to be applicable to the preparation of chemically
5 related compounds. Such processes, when used to prepare a compound of the invention or a pharmaceutically-acceptable salt, or solvate thereof, are provided as a further feature of the invention and are illustrated by the following representative examples in which R_1 , R_2 , R_3 , R_4 , R_5 , X , n , p and q have the same meaning as herein before defined. The reader is referred to Advanced Organic Chemistry, 4th Edition, by Jerry March, published by John Wiley & Sons
10 1992, for general guidance on reaction conditions and reagents. The reader is referred to Protective Groups in Organic Synthesis 2nd Edition, by Green et al, published by John Wiley & Sons for general guidance on protecting groups.

Thus, according to the ninth feature of the invention there is provided a process for preparing a compound of Formula (I), or salt, pro-drug or solvate thereof, which process
15 (wherein n , p , q , X , R_1 , R_2 , R_3 , R_4 and R_5 are unless otherwise specified as defined in Formula (I)) comprises:

a) for compounds of Formula (I) wherein X is $-\text{O}-$, $-\text{S}-$ or $-\text{N}(\text{R}_5)-$, reacting a compound of Formula (A) with a compound of Formula (B),




Formula (A)



Formula (B)

wherein L_1 is a leaving group;

b) for compounds of Formula (I) wherein R_2 is hydrogen, reduction of a compound of Formula (C), wherein R_6 is hydrogen or an alkyl chain,




Formula (C);

- 21 -


c) for compounds of Formula (I) wherein R_2 is C_{1-4} alkyl, reacting a compound of Formula (I) wherein R_2 is hydrogen with a suitable alkylhalide;

d) for compounds of Formula (I) wherein R_2 is hydrogen and R_3 is hydrogen reacting a compound of Formula (D) with an alkylthioacetate, followed by reduction,




Formula (D);

e) for compounds of Formula (I) wherein X is $-S(O_2)N(R_5)-$, reacting a compound of Formula (E) with an amine of Formula (F),




Formula (E)




Formula (F)

wherein L_3 is a displaceable group;

f) for compounds of Formula (I) wherein X is $-N(R_5)S(O_2)-$; reacting an amine of Formula (G) with a compound of Formula (H),




Formula (G)



Formula (H)

wherein L_3 is a displaceable group;

g) for compounds of Formula (I) wherein X is $-S(O)-$, $-S(O_2)-$, oxidising a compound of Formula (J),



Formula (J);

and thereafter if necessary:

- i) converting a compound of the Formula (I) into another compound of the Formula (I);
- ii) removing any protecting groups;
- iii) forming a salt, pro-drug or solvate.

- 5 According to a further aspect of the ninth feature of the invention there is provided the processes a), b), c), d), e), f), and g) described above for the preparation of compounds of the Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII) or Formula (VIII), or a salt, pro-drug or solvate thereof.

Specific reaction conditions for the above reactions are as follows:

- 10 *Process a)* Compounds of Formula (A) and compound of Formula (B) can be reacted together in an organic solvent, at a temperature between room temperature and about 80°C, optionally in the presence of a base such as sodium hydride, potassium carbonate or triethylamine.

- Process b)* The conditions for reduction of a compound of Formula (C) are well known in
15 the art. Examples of reducing agents include hydrogen and a hydrogenation catalyst (for example palladium on carbon), iron and acetic acid, and zinc and hydrochloric acid. The reaction is preferable carried out in the presence of a suitable solvent such as an alcohol, for example methanol or ethanol, and at a temperature in the range of 0-80°C, preferably at or near room temperature.

- 20 *Process c)* Compounds of Formula (I) wherein R₂ is hydrogen and a suitable alkylhalide may be reacted together in a suitable organic solvent such as DMF or DMSO, in the presence of a base, such as sodium hydride or potassium carbonate at a temperature between about room temperature and about 80°C.

- Process d)* Compounds of Formula (D) can be reacted with a alkylthioacetate in the
25 presence of SO₂Cl₂ and in the presence of a bases such as triethylamine, followed by reduction with a suitable reducing agent, such as Raney Nickel in a suitable polar solvent, such as ethanol or methanol at approximately room temperature.

- Process e) and f)* The reaction of compounds of Formula (E) and Formula (F) or the reaction of Formula (G) and Formula (H) where L₃ is a displaceable group is well known in
30 the art, for example they may be reacted in the presence of a base, for example triethylamine, pyridine, or 2,6-di-alkyl-pyridines such as 2,6-lutidine or 2,6-di-*tert*-butylpyridine, and in a suitable solvent, such as DMA, DCM, benzene, THF and DMF. The reaction may

- 23 -

conveniently be performed at a temperature in the range of -40 to 140°C.

Process g) The oxidization of a compound of Formula (J) is well known in the art, for example, reaction with metachloroperbenzoic acid (MCPBA) is the presence of a suitable solvent such as dichloromethane at ambient temperature. If an excess of MCPBA is used a
5 compound of Formula (I) wherein X is —S(O₂)— is obtained.

Intermediates for the processes a), b), c) and d) can be prepared as outlined in Scheme 1, wherein P is protecting group, using the following reaction conditions:


Reaction Conditions (i) Reaction with chloroacetate in an organic solvent such as DMF or acetone, in the presence of a base such as sodium hydride or potassium carbonate at a
10 temperature between approximately room temperature and approximately 80°C.

Reaction Conditions (ii) Reduction using a suitable reducing agent such as hydrogen and a hydrogenation catalyst (for example palladium on carbon), iron and acetic acid, or zinc and hydrochloric acid.

Reaction Conditions (iii) Reaction conditions for the removal of a protecting group are well
15 known in the art.

The compounds used as starting points for the reactions described above are commercially available or they are known compounds or they are prepared by processes known in the art.

- 24 -



Scheme 1

- 25 -

It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, *Protective Groups in Organic Synthesis*, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *t*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed,

- 26 -

for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using
5 conventional techniques well known in the chemical art.

In order to use a compound of the Formula (I) or Formula (II) or Formula (III),
Formula (IV), Formula (V), Formula (VI), Formula (VII) or Formula (VIII) or a
pharmaceutically-acceptable salt or in vivo cleavable ester thereof, for the therapeutic
treatment (including prophylactic treatment) of mammals including humans, it is normally
10 formulated in accordance with standard pharmaceutical practice as a pharmaceutical
composition.

The compositions of the invention may be in a form suitable for oral use (for example
as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible
powders or granules, syrups or elixirs), for topical use (for example as creams, ointments,
15 gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for
example as a finely divided powder or a liquid aerosol), for administration by insufflation (for
example as a finely divided powder) or for parenteral administration (for example as a sterile
aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing
or as a suppository for rectal dosing).

20 The compositions of the invention may be obtained by conventional procedures using
conventional pharmaceutical excipients, well known in the art. Thus, compositions intended
for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or
preservative agents.

Suitable pharmaceutically-acceptable excipients for a tablet formulation include, for
25 example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium
carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding
agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc;
preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as
ascorbic acid. Tablet formulations may be uncoated or coated either to modify their
30 disintegration and the subsequent absorption of the active ingredient within the
gastrointestinal tract, or to improve their stability and/or appearance, in either case, using
conventional coating agents and procedures well known in the art.

Compositions for oral use may be in the form of hard gelatin capsules in which the

- 27 -

active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions generally contain the active ingredient in finely powdered form
5 together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example
10 heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate,
15 anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard
20 paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or
25 wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil,
30 or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and

- 28 -

condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring and preservative agents.

Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.

The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.

Suppository formulations may be prepared by mixing the active ingredient with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Suitable excipients include, for example, cocoa butter and polyethylene glycols.

Topical formulations, such as creams, ointments, gels and aqueous or oily solutions or suspensions, may generally be obtained by formulating an active ingredient with a conventional, topically acceptable, vehicle or diluent using conventional procedures well known in the art.

Compositions for administration by insufflation may be in the form of a finely divided powder containing particles of average diameter of, for example, 30 μ m or much less, the powder itself comprising either active ingredient alone or diluted with one or more physiologically acceptable carriers such as lactose. The powder for insufflation is then conveniently retained in a capsule containing, for example, 1 to 50mg of active ingredient for use with a turbo-inhaler device, such as is used for insufflation of the known agent sodium cromoglycate.

Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.

- 29 -

For further information on formulation the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The size of the dose for therapeutic or prophylactic purposes of a compound of the Formula (I), Formula (II) or Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII) or Formula (VIII) will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.

In using a compound of the Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII) or Formula (VIII) for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.5 mg to 75 mg per kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, 0.5 mg to 20 mg per kg body weight will generally be used. Intravenous administration is however preferred, typically, intravenous doses of about 10 mg to 500 mg per patient of a compound of this invention.

The compounds of this invention may be used in combination with other drugs and therapies used to inhibit and/or reverse and/or alleviate symptom of angiogenesis and/or any disease state associated with angiogenesis. Examples of such disease states include: cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation, endometriosis, dysfunctional uterine bleeding and ocular diseases with retinal vessel proliferation.

- 30 -

If formulated as a fixed dose such combination products employ the compounds of this invention within the dosage range described herein and the other pharmaceutically-active agent within its approved dosage range. Sequential use is contemplated when a combination formulation is inappropriate.

5 According to the tenth feature of the present invention there is provided a compound of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII) or Formula (VIII), or salt, pro-drug or solvate thereof, preferably in the form of a pharmaceutical composition, when dosed in divided doses (also known as split doses) produces a greater anti-tumour effect than when a single dose is given.

10 Anti-tumour effects include but are not limited to, inhibition of tumour growth, tumour growth delay, regression of tumour, shrinkage of tumour, increased time to re-growth of tumour on cessation of treatment, slowing of disease progression. It is expected that when a method of treatment of the present invention is administered to a warm-blooded animal such as a human, in need of treatment for cancer involving a solid tumour, said method of
15 treatment will produce an effect, as measured by, for example, one or more of: the extent of the anti-tumour effect, the response rate, the time to disease progression and the survival rate.

 According to a further aspect of the tenth feature of the present invention there is provided a method for the production of a vascular damaging effect in a warm-blooded animal such as a human, which comprises administering to said animal in divided doses an effective
20 amount of a compound of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII) or Formula (VIII), or salt, pro-drug or solvate thereof, preferably in the form of a pharmaceutical composition.

 According to a further aspect of the tenth feature of the present invention there is provided a method for the treatment of a cancer involving a solid tumour in a warm-blooded
25 animal such as a human, which comprises administering to said animal in divided doses an effective amount of a compound of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII) or Formula (VIII), or salt, pro-drug or solvate thereof, preferably in the form of a pharmaceutical composition.

 According to a further aspect of the tenth feature of the present invention there is
30 provided a medicament comprising two or more fractions of doses of a compound of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII) or Formula (VIII), or salt, pro-drug or solvate thereof, preferably in the form of a pharmaceutical

- 31 -

composition, which together add up to a total daily dose, for administration in divided doses for use in a method of treatment of a human or animal body by therapy.

According to a further aspect of the tenth feature of the present invention there is provided a kit comprising two or more fractions of doses of a compound of Formula (I),
5 Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII) or Formula (VIII), or salt, pro-drug or solvate thereof, preferably in the form of a pharmaceutical composition, which together add up to a total daily dose, for administration in divided doses.

According to a further aspect of the tenth feature of the present invention there is provided a kit comprising:

- 10 a) two or more fractions of doses of a compound of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII) or Formula (VIII), or salt, pro-drug or solvate thereof, , which together add up to a total daily dose, in unit dosage forms for administration in divided doses;
b) container means for containing said dosage forms.

15 According to a further aspect of the tenth feature of the present invention there is provided a kit comprising:

- a) two or more fractions of doses of a compound of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII) or Formula (VIII), or salt, pro-drug or solvate thereof, , which together add up to a total daily dose, together with a
20 excipient or carrier, in unit dosage forms; and
b) container means for containing said dosage forms.

According to a further aspect of the tenth feature of the present invention there is provided the use of a compound of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII) or Formula (VIII), or salt, pro-drug or solvate
25 thereof, in the manufacture of a medicament for administration in divided doses for use in the production of a vascular damaging effect in a warm-blooded animal such as a human.

According to a further aspect of the tenth feature of the present invention there is provided the use of a compound of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII) or Formula (VIII), or salt, pro-drug or solvate
30 thereof, in the manufacture of a medicament for administration in divided doses for use in the production of an anti-cancer effect in a warm-blooded animal such as a human.

According to a further aspect of the tenth feature of the present invention there is provided the use of a compound of Formula (I), Formula (II), Formula (III), Formula (IV),

- 32 -

Formula (V), Formula (VI), Formula (VII) or Formula (VIII), or salt, pro-drug or solvate thereof, in the manufacture of a medicament for administration in divided doses for use in the production of an anti-tumour effect in a warm-blooded animal such as a human.

Divided doses, also called split doses, means that the total dose to be administered to a warm-blooded animal, such as a human, in any one day period (for example one 24 hour period from midnight to midnight) is divided up into two or more fractions of the total dose and these fractions are administered with a time period between each fraction of about greater than 0 hours to about 10 hours, preferably about 1 hour to about 6 hours, more preferably about 2 hours to about 4 hours. The fractions of total dose may be about equal or unequal.

10 Preferably the total dose is divided into two parts which may be about equal or unequal.

The time intervals between doses may be for example selected from:
about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 5.5 hours and about 6 hours.

15 The time intervals between doses may be any number (including non-integers) of minutes between greater than 0 minutes and 600 minutes, preferably between 45 and 375 minutes inclusive. If more than two doses are administered the time intervals between each dose may be about equal or unequal.

Preferably two doses are given with a time interval in between them of greater than
20 or equal to 1 hour and less than 6 hours.

More preferably two doses are given with a time interval in between them of greater than or equal to two hours and less than 5 hours.

Yet more preferably two doses are given with a time interval in between them of greater than or equal to two hours and less than or equal to 4 hours.

25 Particularly the total dose is divided into two parts which may be about equal or unequal with a time interval between doses of greater than or equal to about two hours and less than or equal to about 4 hours.

More particularly the total dose is divided into two parts which may be about equal with a time interval between doses of greater than or equal to about two hours and less than or
30 equal to about 4 hours.

For the avoidance of doubt the term 'about' in the description of time periods means the time given plus or minus 15 minutes, thus for example about 1 hour means 45 to 75

- 33 -

minutes, about 1.5 hours means 75 to 105 minutes. Elsewhere the term 'about' has its usual dictionary meaning.

Although the compounds of the Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII) or Formula (VIII) are primarily of value as therapeutic agents for use in warm-blooded animals (including man), they are also useful whenever it is required to inhibit and/or reverse and/or alleviate symptom of angiogenesis and/or any disease state associated with angiogenesis. Thus, they are useful as pharmacological tools for use in the development of new biological tests and in the search for new pharmacological agents.

10

Biological Assay

Colchicine Binding site competitive assay kit.

The ability of a ligand to bind specifically to the colchicine binding site on tubulin, an indicator of the vascular damaging activity, was assessed using a size exclusion chromatography assay kit from "Cytoskeleton" (1650 Fillmore St. #240, Denver, CO 80206, U.S.A.) Catalogue number of kit: BK023.

The following reagents were used:

- tubulin buffer, to give 0.1mM GTP, 0.5mM MgCl₂, 0.5mM EGTA, 40mM PIPES buffer at pH6.9 in the final reaction mix;
- 20 purified tubulin protein from bovine brain at 1mg/ml in tubulin buffer;
- 0.02mM fluorescent colchicine in tubulin buffer [FITC (fluorescein isothiocyanate)-labelled];
- 2mM colchicine in tubulin buffer;
- 0.2mM vinblastine in tubulin buffer; and
- 25 G-25 Sephadex™ Fine - particle size 34-138µm.

The reaction was performed as follows:

- 8µl of test compound (dissolved in DMSO) was gently mixed with 150µl of tubulin. This was then incubated at 37°C for 30 minutes. Then 4µl of the fluorescent colchicine was added, the incubation mix vortexed for 5 seconds and then incubated for a further 30 minutes at 37°C.
- 30 At the end of the reaction incubation size exclusion chromatography was performed to separate the tubulin with fluorescent colchicine bound from the free, unbound colchicine. If a

- 34 -

test compound inhibited fluorescent colchicine binding then a reduced signal is measured and the compound is confirmed as a colchicine site binding moiety.

Chromatography was performed as follows, using chromatography columns filled with 3mls of G-25 Sephadex™ Fine slurry. The incubation mixture was pipetted onto the column
5 and up to 12 elutions of 160µl were collected. The fluorescence of the tubulin-containing fractions was detected on a spectrophotometer which excites at 485nm and emits at 535nm. Control incubations were also performed, 8µl DMSO (negative control) and 8µl colchicine stock (positive competition control), instead of the 8µl of test compound in the incubation mixture.

10 The degree of competition of colchicine binding by either unlabelled colchicine or test compound was calculated relative to the DMSO negative control.

Compounds of Formula (I) encompass vascular damaging agents and pro-drugs of vascular damaging agents. Pro-drugs of vascular damaging agents are believed to be cleaved *in-vivo*. Without being bound by theoretical considerations these pro-drugs may have lower
15 activity in the in-vitro colchicine binding site competitive assay, than would be anticipated when the activity of these compounds is measured in cell based assays or *in-vivo*.

The invention will now be illustrated in the following non-limiting Examples in which, unless otherwise stated:

- (i) evaporations were carried out by rotary evaporation in vacuo and work-up
20 procedures were carried out after removal of residual solids such as drying agents by filtration;
- (ii) operations were carried out at ambient temperature, that is in the range 18-25°C and under an atmosphere of an inert gas such as argon or nitrogen;
- (iii) yields are given for illustration only and are not necessarily the maximum attainable;
- 25 (iv) the structures of the end-products of the Formula I were confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; proton magnetic resonance chemical shift values were measured on the delta scale and peak multiplicities are shown as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad; q, quartet, quin, quintet;
- 30 (v) intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), high-performance liquid chromatography (HPLC), infra-red (IR) or NMR analysis;

- 35 -

(vi) flash chromatography was performed on silica (Merck Kieselgel: Art.9385);

(vii) OASIS™ is a macroporous co-polymer, used to purify hydrophilic compounds, made from a balanced ratio of lipophilic divinylbenzene and hydrophilic N-vinylpyrrolidone. OASIS™ is described in the following patents, US Patent Number
5 No.5882521, US Patent Number No.5976376 and US Patent Number No.6106721. OASIS™ sample extraction products were obtained from Waters Corporation (Milford, Massachusetts, USA).

(viii) HP20SS resin (DIAION® HP20SS) was obtained from Mitsubishi Chemical America Inc.

10

Abbreviations

4-Dimethylaminopyridine	DMAP
1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride	EDCI
Dimethyl sulphoxide	DMSO
15 Trifluoroacetic acid	TFA
N-(9-fluorenylmethoxycarbonyl)	N-FMOC
N-tert-Butoxycarbonyl	N-Boc
Potassium tert-butyrate	tBuOK

20

- 36 -

Example 1**5-(phenylsulfanyl)-1,3-dihydro-2H-indol-2-one**

3

Example 1


- 5 A suspension of **3** (1.52 g ; 5.2 mmol) and zinc (1.38 g ; 21 mmol) in 50 % H₂SO₄ (20 ml) and ethanol (30ml) was heated at 100°C for 10 hours. After evaporation of ethanol, the mixture was extracted with AcOEt and purified by flash chromatography eluting with CH₂Cl₂ / EtOH 96/4 to give 5-(phenylsulfanyl)-1,3-dihydro-2H-indol-2-one.

Yield : 31 %

- 10 ¹H NMR (CDCl₃) : 3.52 (s, 2H) ; 6.84 (d, 1H) ; 7.1-7.4 (m, 7H) ; 8.04 (s, 1H).

MS-ESI : 240 [M-H]⁻

The starting material was prepared as follows :



1

2

3

15

- A suspension of t-BuOK (6.73 g ; 60 mmol) in THF (70 ml) was cooled to -40°C under argon and treated with a solution of **1** (5.78 g ; 25 mmol) and ethyl chloroacetate (3.7 g ; 30 mmol) in THF (30 ml). The mixture was stirred at -40°C for 2 hours. HCl (2N ; 40 ml) was added and the mixture was stirred at ambient temperature for 15 minutes and extracted with AcOEt / H₂O. The organic phase was evaporated and purified by flash chromatography eluting with petroleum ether / AcOEt 90/10 to give **2**.

Yield : 33 %

¹H NMR spectrum (CDCl₃) : 1.24 (t, 3H) ; 3.92 (s, 2H) ; 4.15 (q, 2H) ; 7.03 (d, 1H) ; 7.08 (dd, 1H) ; 7.43-7.48 (m, 3H) ; 7.52-7.56 (m, 2H) ; 8.01 (d, 1H).

- 25 MS - ESI : 316 [M-H]⁻

A solution of **2** (2.61 g ; 8.2 mmol) in dioxan (25 ml) was treated with NaOH (2N, 5.4 ml) at ambient temperature for 5 hours. The solution was acidified to pH 2 with 6N HCl and

- 37 -


extracted with AcOEt and purified by flash chromatography, eluting with CH₂Cl₂ / EtOH 96/4 to give **3**.

Yield : 64 %

¹H NMR spectrum (CDCl₃) : 3.96 (s, 2H) ; 1.01 (d, 1H) ; 7.09 (dd, 1H) ; 7.43-7.49 (m, 3H) ;
 5 7.52-7.58 (m, 2H) ; 8.03 (d, 1H).

Example 2

5-(4-aminophenoxy)-1,3-dihydro-2H-indol-2-one



10

5

Example 2

Fe (0.387 g ; 6.9 mmol) was added to a solution of **5** (0.4 g ; 1.1 mmol) in AcOH (10 ml). The mixture was heated at 80°C for 30 minutes and evaporated to dryness. The residue was taken up in water. The solution was adjusted to pH 7.5 with sat. NaHCO₃ and extracted with AcOEt. The residue was purified by flash chromatography eluting with CH₂Cl₂ / MeOH 97/3 to give
 15 5-(4-aminophenoxy)-1,3-dihydro-2H-indol-2-one.

Yield : 41 %

¹H NMR spectrum (CDCl₃) : 3.43 (s, 2H) ; 4.89 (s, 2H) ; 6.55 (d, 2H) ; 6.66-6.76 (m, 4H) ;
 6.78 (d, 1H) ; 10.24 (s, 1H).

MS - ESI : 241 [M+H]⁺


20

The starting material **5** was prepared from **4** as described in example 1.

Yield : 28 %

¹H NMR spectrum (CDCl₃) : 1.27 (t, 3H) ; 4.01 (s, 2H) ; 4.19 (q, 2H) ; 7.01 (d, 1H) ; 7.09 (dd, 1H) ; 7.18 (d, 2H) ; 8.22 (d, 1H) ; 8.30 (d, 2H).


25



4

5

- 38 -

Example 3**5-(4-aminophenylsulfanyl)-1,3-dihydro-2H-indol-2-one**

5 was prepared as described for example 2 but using 7 in replacement of 5.


Yield : 14 %

¹H NMR spectrum (CDCl₃) : 3.47 (s, 2H) ; 3.77 (s, 2H) ; 6.62 (d, 2H) ; 6.74 (d, 1H) ; 7.10 (s, 1H) ; 7.14 (d, 1H) ; 7.25 (d, 2H) ; 7.70 (d, 1H).

MS - ESI : 255 [M-H]⁻


10

The starting material 7 was prepared as described in example 2 for 5 starting from 6.



¹H NMR spectrum (CDCl₃) : 1.27 (t, 3H) ; 3.98 (s, 2H) ; 4.18 (q, 2H) ; 7.3-7.7 (4H) ; 8-8.3 (m, 3H).

15

Example 4**5-(4-N-glutaminyaminophenoxy)-1,3-dihydro-2H-indol-2-one**

20

10

Example 4

A solution of 10 (0.2 g ; 0.47 mmol) in solution in CH₂Cl₂ (1 ml) was treated with a solution of HCl (20 %) in dioxan (2.5 ml). After stirring at ambient temperature for 2 hours the mixture was evaporated and purified on HP20SS resin, eluting with water to give 5-(4-N-glutaminyaminophenoxy)-1,3-dihydro-2H-indol-2-one.

25 Yield : 81 %


- 39 -

^1H NMR spectrum (DMSO-d_6) : 2.01-2.13 (m, 2H) ; 2.39 (t, 2H) ; 3.47 (s, 2H) ; 3.93-4.05 (m, 1H) ; 6.80 (d, 1H) ; 6.85 (dd, 1H) ; 6.93 (d, 1H) ; 6.96 (d, 2H) ; 7.58 (d, 2H) ; 8.34 (bs, 2H) ; 10.37 (s, 1H) ; 10.55 (s, 1H) ; 12.35 (bs, 1H).

MS - ESI : 368 $[\text{M-H}]^-$

5	Elemental analysis	Found	C 53.21	H 5.05	N 9.93	Cl 7.96
	$\text{C}_{19}\text{H}_{19}\text{N}_3\text{O}_5$, 0.91 H_2O , 0.95 HCl	Requires	C 54.28	H 5.22	N 9.99	Cl 8.01

10 The starting material was prepared as follows :



A solution of 5-(4-aminophenoxy)-1,3-dihydro-2H-indol-2-one (Example 2) (0.24 g ; 1 mmol), **8** (0.638 g ; 1.5 mmol), EDCI (0.288 g ; 1.5 mmol) and DMAP (0.005 g ; 0.02 mmol) in CH_2Cl_2 (7 ml) was stirred under argon for 2 hours. The mixture was purified by flash chromatography eluting with CH_2Cl_2 / MeOH 98/2 to give **9** which was redissolved in CHCl_3 (3.5 ml) and treated with piperidine (1 ml). After stirring for 1 h 30, the mixture was diluted with water and extracted with CH_2Cl_2 . The organic phase was purified by flash chromatography eluting with CH_2Cl_2 / MeOH 95/5 to give **10**.

20 Yield : 47 %/

^1H NMR spectrum (DMSO-d_6) : 1.39 (s, 9H) ; 1.59-1.72 (m, 1H) ; 1.80-1.92 (m, 1H) ; 2.21-2.39 (m, 2H) ; 3.25-3.33 (m, 2H) ; 3.46 (s, 2H) ; 6.79 (d, 1H) ; 6.83 (dd, 1H) ; 6.89-6.93 (m, 3H) ; 7.60 (d, 2H) ; 9.85 (bs, 1H) ; 10.33 (s, 1H).

MS - ESI : 424 $[\text{M-H}]^-$

- 40 -

Example 5**5-(4-N-Serylamino-phenoxy)-1,3-dihydro-2H-indol-2-one**


- 5 A solution of **12** (0.21 g ; 0.49 mmol) in CH₂Cl₂ (2 ml) was treated with a solution of HCl / dioxan (2,4 N ; 2 ml). After stirring at ambient temperature for 2 h 30, the mixture was evaporated to dryness. The residue was taken up in water, DMF and purified on HP20SS resin after neutralisation to pH 7.5 with 0.5 N NaOH. After elution with CH₃CN / H₂O 50/50, the appropriate fractions were acidified to pH 3 and freeze dried to give 5-(4-N-Serylamino-phenoxy)-1,3-dihydro-2H-indol-2-one.

Yield : 64 %

¹H NMR spectrum (DMSO-d₆) : 3.47 (s, 2H) ; 3.81-3.87 (m, 2H) ; 3.99 (bs, 1H) ; 5.56 (bs, 1H) ; 6.80 (d, 1H) ; 6.84 (dd, 1H) ; 6.92 (s, 1H) ; 6.95 (d, 2H) ; 7.60 (d, 2H) ; 8.27 (bs, 2H) ; 10.36 (s, 1H) ; 10.61 (s, 1H).

- 15 MS - ESI : 328 [M+H]⁺

The starting material was prepared as follows :



- 20 A solution of 5-(4-aminophenoxy)-1,3-dihydro-2H-indol-2-one (Example 2) (0.24 g ; 1 mmol), **11** (0.267 g ; 1 mmol), EDCI (0.346 g ; 1.8 mmol) and DMAP (0.020 g ; 0.16 mmol) in CH₂Cl₂ (5 ml) was stirred under argon overnight. The mixture was purified by flash chromatography eluting with CH₂Cl₂ / MeOH 97/3 to give **12**.
- Yield : 50 %
- 25 ¹H NMR spectrum (DMSO-d₆) : 1.38 (s, 9H) ; 3.46 (s, 2H) ; 3.5 (bs, 2H) ; 4.07-4.18 (m, 1H) ; 4.92 (t, 1H) ; 6.73 (d, 1H) ; 6.78 (d, 1H) ; 6.82 (d, 1H) ; 6.88-6.95 (m, 3H) ; 7.58 (d, 2H) ; 9.91 (s, 1H) ; 10.32 (s, 1H).

Example 6**5-(4-N-Glycylaminophenoxy)-1,3-dihydro-2H-indol-2-one**

Example 6

5

14

A solution of **14** (0.681 g ; 1.71 mmol) in CH₂Cl₂ (2 ml) was treated with a solution of HCl / dioxan (2.4 N ; 6 ml). The mixture was stirred at ambient temperature for 1 hour and evaporated. The residue was taken up in DMF / H₂O, neutralised to pH 7 with 2N NaOH and purified on reverse phase silica eluting with a gradient of CH₃CN / H₂O. The appropriate

10 fractions were acidified to pH 3.2 with 2N HCl and freezer dried to give 5-(4-N-Glycylaminophenoxy)-1,3-dihydro-2H-indol-2-one.

Yield : 43 %


¹H NMR spectrum (DMSOd6) : 3.47 (s, 2H) ; 3.75 (s, 2H) ; 6.80 (d, 1H) ; 6.85 (dd, 1H) ; 6.93 (d, 1H) ; 6.95 (d, 2H) ; 7.57 (d, 2H) ; 8.15 (bs, 2H) ; 10.36 (s, 1H) ; 10.58 (s, 1H).

15 MS - ESI : 298 [M+H]⁺

The starting material was prepared as described for compound **12** but using **13** in replacement of **11**.

Yield : 85 %

20 ¹H NMR spectrum (DMSOd6) : 1.39 (s, 9H) ; 3.47 (s, 2H) ; 3.59 (d, 2H) ; 6.78 (d, 1H) ; 6.83 (dd, 1H) ; 6.89-6.95 (m, 3H) ; 7.03 (t, 1H) ; 7.54 (d, 2H) ; 9.88 (s, 1H) ; 10.32 (s, 1H).




Example 2

13

14

- 42 -

Example 7**5-(4-N-glutaminyaminophenylsulfanyl)-1,3-dihydro-2H-indol-2-one**

5

The compound was prepared as described in example 4 (replacing 10 by **18**).


Yield : 70 %

¹H NMR spectrum (DMSO-d₆) : 1.98-2.15 (m, 2H) ; 2.38 (t, 2H) ; 3.48 (s, 2H) ; 3.94-4.08 (m, 1H) ; 6.85 (d, 1H) ; 7.20-7.31 (m, 4H) ; 7.58 (d, 2H) ; 8.36 (bs, 2H) ; 10.54 (s, 1H) ; 10.80 (s, 1H) ; 12.30 (bs, 1H).

MS - ESI : 384 [M-H]⁻


Elemental analysis	Found	C 51.31	H 4.88	N 9.35	S 6.99	Cl 6.84
C ₁₉ H ₁₉ N ₃ O ₄ S, 1.33 H ₂ O 0.9 HCl	Requires	C 51.61	H 5.14	N 9.50	S 7.25	Cl 7.22

15 The starting material was prepared as described in example 4 starting from example 3.



Yield : 44 %

¹H NMR spectrum (DMSO-d₆) : 1.38 (s, 9H) ; 1.58-1.69 (m, 1H) ; 1.74-1.91 (m, 1H) ; 2.23-2.36 (m, 2H) ; 3.47 (s, 2H) ; 6.82 (d, 2H) ; 7.18-7.27 (m, 4H) ; 7.61 (d, 2H) ; 10.50 (s, 1H).

Example 8**5-(4-hydroxyphenylsulfanyl)-1,3-dihydro-2H-indol-2-one**

25

- 43 -


5-(4-hydroxyphenylsulfanyl)-1,3-dihydro-2*H*-indol-2-one was prepared as described in example 1.

Yield : 30 %

¹H NMR spectrum (DMSO-d₆) : 3.44 (s, 2H) ; 7.73-7.79 (m, 3H) ; 7.03-7.15 (m, 2H) ; 7.21 (d, 2H) ; 9.69 (s, 1H) ; 10.42 (s, 1H).

MS - ESI : 256 [M-H]⁻

The starting material was prepared as follows:



To a suspension of *t*-BuOK (22.44 g ; 0.2 mmol) in THF (300 ml) at -40°C under argon was added a solution of 4-fluoronitrobenzene (14.1 g ; 0.1 mmol) and ethyl chloroacetate (14.7 g ; 0.12 mmol) in THF (100 ml). After 1 hour at -40°C the mixture was allowed to warm up at -
15 5°C and 2N HCl (200 ml) was added. After extraction with AcOEt / H₂O the organic phase was purified by flash chromatography eluting with petroleum ether / AcOEt to give **20**.

¹H NMR spectrum (CDCl₃) : 1.27 (t, 3H) ; 4.01 (s, 2H) ; 4.19 (q, 2H) ; 7.07 (dd, 1H) ; 7.15 (dd., 1H) ; 8.20 (dd, 1H).

20 A mixture of **20** (2.27 g ; 0.01 mmol), K₂CO₃ (2.07 g ; 0.01 mmol), 4-mercaptophenol (1.5 g ; 0.01 mmol) in N-methyl pyrrolidone (20 ml) was heated at 80°C under argon atmosphere for 3 hours. After extraction with AcOEt / H₂O the organic phase was purified by flash chromatography eluting with petroleum ether / AcOEt 75/25 to give **19**.


Yield : 81 %

25 ¹H NMR spectrum (CDCl₃) : 1.25 (t, 3H) ; 3.92 (s, 2H) ; 4.16 (q, 2H) ; 5.37 (s, 1H) ; 6.90 (d, 2H) ; 6.94 (d, 1H) ; 6.98 (dd, 1H) ; 7.43 (d, 2H) ; 7.99 (d, 1H).

Example 9

6-benzyloxy-1,3-dihydro-2*H*-indol-2-one

- 44 -



5-benzyloxy-1,3-dihydro-2*H*-indol-2-one was prepared as described in example 2 but using **23** in replacement of **5**.


Yield : 54 %

¹H NMR spectrum (CDCl₃) : 3.47 (s, 2H) ; 5.06 (s, 2H) ; 6.53 (d, 1H) ; 6.62 (dd, 1H) ; 7.10 (d, 1H) ; 7.32-7.46 (m, 5H) ; 7.78 (bs, 1H).

MS - ESI : 240 [M+H]⁺

The starting material was prepared as follows :

10



Diethylmalonate (3.78 g ; 23.6 mmol) was added under argon atmosphere dropwise to a suspension of NaH 60 % (0.91 g ; 22.8 mmol) in DMSO (40 ml). The mixture was heated at 80°C for 20 minutes. After cooling, **21** (2.7 g ; 10 mmol) in solution in DMSO (10 ml) was added. The mixture was heated at 100°C for 20 hours acetic acid (1.4 ml) was added and the mixture was extracted with CH₂Cl₂ / 0.5N HCl. The organic phase was evaporated and purified by flash chromatography eluting with petroleum ether / AcOEt 80/20 to give **22**.

Yield : 68 %

¹H NMR spectrum (CDCl₃) : 1.28 (t, 6H) ; 3.36 (s, 1H) ; 4.21 (q, 2H) ; 5.12 (s, 2H) ; 7.23 (dd, 1H) ; 7.35-7.45 (m, 6H) ; 7.66 (d, 1H).

A solution of **22** (2.73 g ; 7 mmol) and LiCl (0.6 g ; 14 mmol) in DMSO (30 ml) and H₂O (0.13 ml) was heated at 80°C overnight. The mixture was extracted with AcOEt / sat NaCl to give after evaporation of the organic phase **23** as an oil which was used without further purification.

Yield : 32 %

¹H NMR spectrum (CDCl₃) : 1.25 (t, 3H) ; 3.93 (s, 2H) ; 4.20 (q, 2H) ; 5.12 (s, 2H) ; 7.17-7 (m, 3H) ; 7.35-7 (m, 4H) ; 7.65 (dd, 1H).

Example 10

6-(3-aminobenzyloxy)-1,3-dihydro-2H-indol-2-one



24

Example 10

5


A mixture of **24** (0.129 g ; 0.454 mmol) and Fe (0.127 g ; 2.27 mmol) in MeOH (3 ml) and 12N HCl (1 ml) was heated at 80°C for 1 h 30. After evaporation and dilution with water, the mixture was neutralised to pH 7.5 with sat NaHCO₃ and extracted with AcOEt. The organic phase was evaporated and purified by flash chromatography eluting with petroleum ether / AcOEt 50/50 to give after evaporation an oil which was triturated with ether and pentane to give 6-(3-aminobenzyloxy)-1,3-dihydro-2*H*-indol-2-one as a solid.

Yield : 30 %

¹H NMR spectrum (DMSO-d₆): 3.63 (s, 2H); 4.91 (s, 2H); 5.22 (bs, 2H); 6.42 (d, 1H); 6.48-6.57 (m, 3H); 6.62 (m, 1H); 7.01 (dd, 1H); 7.07 (d, 1H); 10.31 (s, 1H).

15 MS - ESI : 255 $[M+H]^+$

The starting material was prepared as follows :




26

24

20 A mixture of **26** (0.224 g ; 1.5 mmol), K₂CO₃ (0.228 g ; 1.65 mmol) and **25** (0.558 g ; 1.95 mmol) in DMF (4 ml) was stirred under argon atmosphere for 2 days. The mixture was extracted with H₂O / AcOEt and the organic phase evaporated and purified by flash chromatography eluting with petroleum ether / AcOEt 30/70 to give **24**.

Yield : 40 %

25 ¹H NMR spectrum (DMSO-d₆) : 3.37 (s, 2H) ; 5.25 (s, 2H) ; 6.49 (d, 1H) ; 6.60 (dd, 1H) ; 7.11 (d, 1H) ; 7.71 (dd, 1H) ; 7.91 (d, 1H) ; 8.20 (d, 1H) ; 8.30 (s, 1H) ; 10.38 (s, 1H).

Example 11**5-(3-N-glutaminyaminobenzoyloxy)-1,3-dihydro-2H-indol-2-one**


5-(3-N-glutaminyaminobenzoyloxy)-1,3-dihydro-2H-indol-2-one was prepared described in example 4 starting from 27.

Yield : 42 %

¹H NMR spectrum (DMSOd₆ + AcOd₄) : 2.04-2.16 (m, 2H) ; 2.36-2.45 (m, 2H) ; 3.37 (s, 2H) ; 4.03 (t, 1H) ; 5.09 (s, 2H) ; 6.48 (d, 1H) ; 6.55 (dd, 1H) ; 7.08 (d, 1H) ; 7.19 (d, 1H) ; 7.37 (dd, 1H) ; 7.60 (d, 1H) ; 7.69 (d, 1H) ; 10.30 (s, 1H) ; 10.64 (s, 1H).

MS-ESI : 382 [M-H]⁻

The starting material was prepared using the same method as described for 10 in Example 4 but starting from 6-(3-aminobenzoyloxy)-1,3-dihydro-2H-indol-2-one (Example 10.)



Yield : 69 %

¹H NMR spectrum (DMSOd₆) : 1.4(s, 9H) ; 1.8-1.96 (m, 2H) ; 2.27-2.34 (m, 2H) ; 3.38 (s, 2H) ; 4.08-4.31 (m, 3H) ; 5.07 (s, 2H) ; 6.46 (d, 1H) ; 6.56 (dd, 1H) ; 7.08-7.14 (m, 2H) ; 7.31-7.45 (m, 4H) ; 7.58 (d, 1H) ; 7.68-7.77 (m, 3H) ; 7.91 (d, 2H) ; 10.09 (s, 1H) ; 10.33 (s, 1H)

Example 12**6-benzoyloxy-N-methyl-1,3-dihydro-2H-indol-2-one**

- 47 -



Example 9

Example 12

A mixture of 6-benzyloxy-1,3-dihydro-2*H*-indol-2-one (Example 9) (0.12 g ; 0.5 mmol), K_2CO_3 (0.07 g ; 0.5 mmol) and CH_3I (0.031 ml) in acetone (5 ml) was refluxed under argon atmosphere for 6 hours. After evaporation to dryness, the residue was purified by flash chromatography eluting with petroleum ether / AcOEt 60/40 to give 6-benzyloxy-N-methyl-1,3-dihydro-2*H*-indol-2-one.

Yield : 31 %


1H NMR spectrum : 3.17 (s, 3H) ; 3.46 (s, 2H) ; 5.09 (s, 2H) ; 6.50 (d, 1H) ; 6.62 (dd, 1H) ; 7.12 (d, 1H) ; 7.31-7.49 (m, 5H).

MS-ESI : 254 $[M+H]^+$

Example 13

4-benzyloxy-1,3-dihydro-2*H*-indol-2-one

15



Example 13

To a solution of chlorine (1.47 g ; 0.021 mmol) in CH_2Cl_2 (37 ml) at $-70^\circ C$ was added under argon ethyl methylthioacetate (2 ml ; 0.021 mmol) in CH_2Cl_2 (10 ml). After stirring for 5 minutes, **29** (8.35 g ; 0.042 mmol) in solution in CH_2Cl_2 (40 ml) was added dropwise. The mixture was stirred at $-70^\circ C$ for 1 hour, triethylamine (4.68 ml ; 0.034 mmol) was added. After 30 minutes, the mixture was extracted, the organic phase was evaporated and purified by flash chromatography, eluting with CH_2Cl_2 / AcOEt 90/10 to give a mixture of **30** and **31**, as a side product

The mixture of **30** and **31** (0.74 g ; 2.59 mmol) in solution in EtOH (20 ml) was treated with Ni Raney (2 g) at room temperature for 2 hours. After filtration of the catalyst, the filtrate was

- 48 -

evaporated and purified by flash chromatography, eluting with petroleum ether / AcOEt 60/40 to give 4-benzyloxy-1,3-dihydro-2*H*-indol-2-one.


¹H NMR spectrum (CDCl₃) : 3.53 (s, 2H) ; 5.1 (s, 2H) ; 6.5-6.7 (m, 2H) ; 7.1-7.5 (m, 6H).

MS - ES : 240 [M+H]⁺

5

Example 14

5-(4-phosphonophenylsulfanyl)-1,3-dihydro-2*H*-indol-2-one



- 10 A solution of **32** (0.275 g ; 0.6 mmol) and TFA (1.5 ml) in CH₂Cl₂ (15 ml) was stirred at 0°C for 10 minutes and at room temperature for 15 minutes. After evaporation to dryness, the residue was purified on OASIS resin eluting with a gradient of CH₃CN / H₂O 0-30 % to give 5-(4-phosphonophenylsulfanyl)-1,3-dihydro-2*H*-indol-2-one.

Yield : 63 %

- 15 ¹H NMR Spectrum (DMSO-d₆ + AcOD₄) : 3.48 (s, 2H) ; 6.85 (d, 1H) ; 7.1-7.4 (m, 7H).

MS-ESI : 336 [M-H]⁻


Elemental analysis

Found C 49.10 H 3.68 N 4.45 S 9.19

C₁₄H₁₂NO₅SP, 0.3 H₂O

Requires C 49.07 H 3.71 N 4.09 S 9.36

- 20 The starting material was prepared as follows:



- To a solution of 5-(4-hydroxyphenylsulfanyl)-1,3-dihydro-2*H*-indol-2-one (Example 8) (0.257 g ; 1 mmol) and 1*H*-tetrazole (0.21 g ; 3 mmol) in a mixture of DMF (2 ml) and THF (2 ml) was added under argon atmosphere di-tert-butyl diethylphosphoramidite (560 μl ; 2 mmol). After stirring for one hour, the mixture was cooled to -70°C and magnesium peroxophthalate (0.544 g ; 1.1 mmol) was added portionwise. The mixture was stirred at -70°C for one hour and sat NaHCO₃ (15 ml) was added. After 15 minutes, the mixture was extracted

- 49 -

with AcOEt. The organic phase was evaporated and purified by flash chromatography eluting with CH_2Cl_2 / EtOH 98/2 to give **1**.


Yield : 61 %.

^1H NMR Spectrum (DMSO-d_6) : 1.44 (m, 9H) ; 3.50 (s, 2H) ; 6.86 (d, 1H) ; 7.1-7.4 (m, 6H)..

5 MS-ESI : 448 $[\text{M-H}]^-$

Claims

1. The use of a compound of Formula (I) for the manufacture of a medicament to inhibit and/or reverse and/or alleviate symptom of angiogenesis and/or any disease state associated with angiogenesis, wherein:



Formula (I)

X is selected from: —O—, —S—, —S(O)—, —S(O₂)—, —N(R₅)—, —C(O)—, —C(O)N(R₅)—, —N(R₅)C(O)—, —S(O₂)N(R₅)—, or —N(R₅)S(O₂)—;

R₁ is independently selected from: amino, halo, hydroxy,

—OPO₃H₂, C₁₋₄alkyl, or C₁₋₄alkoxy, wherein the amino group is optionally substituted by an amino acid residue and the hydroxy group is optionally esterified;

R₂ is selected from: hydrogen or C₁₋₄alkyl;

R₃ is selected from: hydrogen, halo, hydroxy, hydroxyC₁₋₄alkyl, cyano,

cyanoC₁₋₄alkyl, carboxy, carboxyC₁₋₄alkyl, C₁₋₄alkanoyl, C₁₋₄alkanoylC₁₋₄alkyl, carbamoyl, carbamoylC₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, C₁₋₄alkoxycarbonylC₁₋₄alkyl, C₁₋₄alkoxycarbonylamino, amino, N-C₁₋₄alkylamino, NN-diC₁₋₄alkylamino, aminoC₁₋₄alkyl, N-C₁₋₄alkylaminoC₁₋₄alkyl, NN-diC₁₋₄alkylaminoC₁₋₄alkyl, ureido, or C₁₋₄alkylureylene;

R₄ is independently selected from: C₁₋₄alkyl, C₁₋₄alkoxy or halo;

R₅ is selected from: hydrogen or C₁₋₄alkyl;

n is 0 or 1;

p is 0, 1, 2 or 3; and


q is 0, 1 or 2;

or a salt, pro-drug or solvate thereof.

2. The use of a compound according to Claim 1, or a salt, pro-drug or solvate thereof, wherein X is —O—, —S—, —S(O)—, or —S(O₂)—.

- 51 -

3. The use of a compound according to Claim 1 or Claim 2, or a salt, pro-drug or solvate thereof, wherein R^3 is hydrogen.
- 5 4. The use of a compound according to any one of the preceding claims, or a salt, pro-drug or solvate thereof, wherein R^1 is amino, hydroxy, $-\text{OPO}_3\text{H}_2$, or C_{1-4} alkoxy, wherein the amino group is optionally substituted by an amino acid residue and the hydroxy group is optionally esterified.
- 10 5. The use of a compound according to Claim 4, or a salt, pro-drug or solvate thereof, wherein R^1 is amino substituted by an amino acid residue or is an esterified hydroxy group.
6. The use of a compound according to Claim 5, or a salt, pro-drug or solvate thereof,
15 wherein R^1 is amino substituted by an amino acid residue and the amino acid residue is derived from glutamic acid, serine, threonine, arginine, glycine, alanine, β -alanine or lysine.
7. The use of a compound according to Claim 4, or a salt, pro-drug or solvate thereof,
20 wherein R^1 is C_{1-4} alkoxy.
8. The use of a compound of Formula (IIa), or a pharmaceutically-acceptable salt, pro-drug or solvate thereof, as a medicament,



Formula (IIa)

wherein: n , q , X , R_1 , R_2 , R_3 , R_4 and R_5 are as defined in Claim 1; and


p is 1, 2 or 3

with the proviso that:

- 52 -

- (i) when p is 1, R_1 cannot be halo or methyl, and when p is 2, $(R_1)_p$ cannot be di-halo or di-methyl;
- (ii) when X is $—S(O_2)N(R_5)—$, $—N(R_5)S(O_2)—$, $—N(R_5)C(O)—$ or $—C(O)—$, n is 0 or 1, R_2 is hydrogen, R_3 is hydrogen, q is 0 or q is 1 and R_4 is 5-chloro and R^5 is hydrogen, then $(R_1)_p$ cannot be 2-methoxy, 3-methoxy, 4-methoxy, 4-nitro, 4-hydroxy, 4-amino, 3-chloro-4-methoxy or 3-chloro-4-ethoxy; and
- (ii) when X is linked at the 7-position of the oxindole ring, X is $—O—$, n is 0, R_2 is hydrogen, R_3 is hydrogen or methyl and q is 0, then $(R_1)_p$ cannot be 2-methoxy, 2-amino, or 3,4,5-tri-methoxy;
- or a pharmaceutically-acceptable salt, pro-drug or solvate thereof.

9. A compound of Formula (IIa) as defined in Claim 8, or salt, pro-drug or solvate thereof.
10. A compound of Formula (III), wherein:




Formula (III)

- X is selected from: $—S—$, $—S(O)—$, or $—S(O_2)—$;
- and wherein R^1 , R^2 , R^3 , R^4 , n , p and q are as defined in Claim 1;
- with the proviso that the following compounds are excluded:
- 7-(phenylsulfanyl)-1,3-dihydro-2H-indol-2-one;
 - 7-(2-chlorophenylsulfanyl)-1,3-dihydro-2H-indol-2-one;
 - 7-(4-chlorophenylsulfanyl)-1,3-dihydro-2H-indol-2-one;
 - 7-(benzylsulfanyl)-1,3-dihydro-2H-indol-2-one;
 - 7-(phenylsulfinyl)-1,3-dihydro-2H-indol-2-one;
 - 7-(2-chlorophenylsulfinyl)-1,3-dihydro-2H-indol-2-one;
 - 7-(4-chlorophenylsulfinyl)-1,3-dihydro-2H-indol-2-one;
 - 7-(phenylsulfonyl)-1,3-dihydro-2H-indol-2-one; and
 - 7-(4-chlorophenylsulfonyl)-1,3-dihydro-2H-indol-2-one;

- 53 -

or a salt, pro-drug or solvate thereof.

11 A compound of Formula (V), wherein:



Formula (V)

wherein R^1 , R^2 , R^3 , R^4 , R^5 , n , p and q are as defined in Claim 1;

with the proviso that:

- (i) when $-(CH_2)_nO-$ is linked at the 4-position of the oxindole ring, n is 0, p is 0 and R_2 and R_3 are each independently hydrogen and q is 1 then R_4 cannot be 7-chloro;
- (ii) when $-(CH_2)_nO-$ is linked at the 5-position of the oxindole ring, n is 0 or 1, R_2 is hydrogen or methyl, R_3 is hydrogen and q is 0, then p cannot be 0 and $(R_1)_p$ cannot be 2-chloro or 4-chloro;
- (iii) when $-(CH_2)_nO-$ is linked at the 6-position of the oxindole ring, n is 1, p is 0, R_2 is hydrogen or methyl, R_3 is hydrogen and q is 1 then R_4 cannot be 5-methoxy; and
- (iv) when $-(CH_2)_nO-$ is linked at the 7-position of the oxindole ring, n is 0 or 1, R_2 is hydrogen or methyl, R_3 is hydrogen and q is 0, then p cannot be 0 and $(R_1)_p$ cannot be 2-chloro, 2-fluoro, 2-amino, 2,6-dichloro or 3,4,5-trimethoxy;

or a salt, pro-drug or solvate thereof.

12 A compound according to Claim 9 or Claim 10, or a salt, pro-drug or solvate thereof, wherein R^3 is hydrogen.

13. A compound according to any one of claims 9 to 11, or a salt, pro-drug or solvate thereof, wherein R^1 is amino, hydroxy, $-OPO_3H_2$, or C_{1-4} alkoxy, wherein the amino group is optionally substituted by an amino acid residue and the hydroxy group is optionally esterified.


- 54 -

14. A compound according to Claim 13, or a salt, pro-drug or solvate thereof, wherein R¹ is amino substituted by an amino acid residue or C₁₋₄alkoxy.
15. A compound according to Claim 14, or a salt, pro-drug or solvate thereof, wherein R¹ is amino substituted by an amino acid residue and the amino acid residue is derived from glutamic acid, serine, threonine, arginine, glycine, alanine, β-alanine or lysine.
16. A compound according to Claim 13, or a salt, pro-drug or solvate thereof, wherein R¹ is C₁₋₄alkoxy.
17. A compound selected from:
5-(phenylsulfanyl)-1,3-dihydro-2*H*-indol-2-one ;
5-(4-aminophenoxy)-1,3-dihydro-2*H*-indol-2-one ;
5-(4-aminophenylsulfanyl)-1,3-dihydro-2*H*-indol-2-one;
5-(4-hydroxyphenylsulfanyl)-1,3-dihydro-2*H*-indol-2-one; and
6-(3-aminobenzyloxy)-1,3-dihydro-2*H*-indol-2-one;
5-(4-N-glutaminyaminophenoxy)-1,3-dihydro-2*H*-indol-2-one;
5-(4-N-Serylaminophenoxy)-1,3-dihydro-2*H*-indol-2-one;
5-(4-N-Glycylaminophenoxy)-1,3-dihydro-2*H*-indol-2-one;
5-(4-N-glutaminyaminophenylsulfanyl)-1,3-dihydro-2*H*-indol-2-one;
5-(3-N-glutaminyaminobenzyloxy)-1,3-dihydro-2*H*-indol-2-one; and
5-(4-phosphonophenylsulfanyl)-1,3-dihydro-2*H*-indol-2-one;
or a salt, prodrug or solvate thereof.
18. A pharmaceutical composition comprising a compound according to any one of claims 9 to 17 or a pharmaceutically-acceptable salt, pro-drug, or solvate thereof, in admixture with a pharmaceutically-acceptable diluent or carrier.
19. The use of a compound of Formula (I) as defined in Claim 1, or salt, pro-drug or solvate thereof, in the manufacture of a medicament for administration in divided doses for use in the production of an anti-tumour effect in a warm-blooded animal.


- 55 -

20. A process for preparing a compound of Formula (I), or salt, pro-drug or solvate thereof, which process (wherein n, p, q, X, R₁, R₂, R₃, R₄ and R₅ are unless otherwise specified as defined in Claim I) comprising:

- a) for compounds of Formula (I) wherein X is —O—, —S— or —N(R₅)—, reacting a
5 compound of Formula (A) with a compound of Formula (B),




Formula (A)



Formula (B)


wherein L₁ is a leaving group;

- b) for compounds of Formula (I) wherein R₂ is hydrogen, reduction of a compound of
10 Formula (C), wherein R₆ is hydrogen or an alkyl chain,



Formula (C);


- c) for compounds of Formula (I) wherein R₂ is C₁₋₄alkyl, reacting a compound of
Formula (I) wherein R₂ is hydrogen with a suitable alkylhalide;
15 d) for compounds of Formula (I) wherein R₂ is hydrogen and R₃ is hydrogen reacting a
compound of Formula (D) with an alkylthioacetate, followed by reduction,




Formula (D);

- e) for compounds of Formula (I) wherein X is —S(O₂)N(R₅)—, reacting a compound of
20 Formula (E) with an amine of Formula (F),

- 56 -




Formula (E)




Formula (F)

wherein L_3 is a displaceable group;

f) for compounds of Formula (I) wherein X is $-N(R_5)S(O_2)-$, reacting an amine of
 5 Formula (G) with a compound of Formula (H),




Formula (G)



Formula (H)

wherein L_3 is a displaceable group;

g) for compounds of Formula (I) wherein X is $-S(O)-$, $-S(O_2)-$, oxidising a
 10 compound of Formula (J),



Formula (J).

and thereafter if necessary:

i) converting a compound of the Formula (I) into another compound of the Formula (I);

15 ii) removing any protecting groups;

iii) forming a salt, pro-drug or solvate.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 02/00947A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D209/34 A61K31/404 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 01 56607 A (EISAI CO., LTD., JAPAN) 9 August 2001 (2001-08-09) see Benzenesulfonamide, N-(2,3-dihydro-2-oxo-1H-indol-7-yl)-4-methyl- see formula (I)	1,3-9, 19,20
X	PATENT ABSTRACTS OF JAPAN vol. 2000, no. 14, 5 March 2001 (2001-03-05) -& JP 2000 309534 A (EISAI CO LTD), 7 November 2000 (2000-11-07) abstract see Benzenesulfonamide, N-(2,3-dihydro-2-oxo-1H-indol-7-yl)-4-methyl- see formula (I)	1,3-9, 19,20

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

6 June 2002

Date of mailing of the international search report

21/06/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Schmid, J-C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/00947

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	OWA T ET AL: "A focused compound library of novel N-(7-indolyl)benzenesulfonamides for the discovery of potent cell cycle inhibitors" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 11, June 2000 (2000-06), pages 1223-1226, XP004200561 ISSN: 0960-894X see compounds 5,12,26 table 1	1,3-9, 19,20
X	EP 0 673 937 A (EISAI CO., LTD., JAPAN) 27 September 1995 (1995-09-27) claims; example 6	1,3-9, 19,20
X	WALSH, DAVID A. ET AL: "Antiinflammatory agents. 4. Syntheses and biological evaluation of potential pro-drugs of 2-amino-3-benzoylbenzeneacetic acid and 2-amino-3-(4-chlorobenzoyl)benzeneacetic acid" J. MED. CHEM. (1990), 33(8), 2296-304 , XP001071284 see compounds 11,12 table I	1
X	US 4 006 161 A (HOLMES RICHARD E ET AL) 1 February 1977 (1977-02-01) claims	8-12
X	WO 94 27963 A (HOECHST ROUSSEL PHARMA) 8 December 1994 (1994-12-08) example 14	11
X	FRETER ET AL.: "Oxindole Analogs of (5-Hydroxy)-tryptamine and -tryptophan as Inhibitors of the Biosynthesis and Breakdown of Serotonin" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 80, 1958, pages 982-987, XP001071061 ISSN: 0002-7863 see compound IIb page 984	11
X	EP 0 255 178 A (BLASCHIM SPA) 3 February 1988 (1988-02-03) example 5	11

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 02/00947

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 008 226 A (FUJISAWA PHARMACEUTICAL CO) 20 February 1980 (1980-02-20) see formulae 'le!', 'lc'! page 6; examples page 102, line 28 page 48, line 26,27 ----	10,11
X	US 4 472 433 A (UEDA IKUO ET AL) 18 September 1984 (1984-09-18) column 2, line 15 - line 29 column 22, line 26 - line 36 column 38, line 15 - line 45 ----	1-4, 7-14,16, 18,20
X	HEATHER M. NONHEBEL ET AL.: "Indole-3-acetic Acid Catabolism in Zea mays Seedlings" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 260, no. 23, 15 October 1985 (1985-10-15), pages 12685-12689, XP001080722 page 12685, right-hand column -page 12686, left-hand column ----	11
A	WO 00 41669 A (ANGIOGENE PHARM LTD ;DAVIS PETER DAVID (GB)) 20 July 2000 (2000-07-20) cited in the application the whole document ----	1-20
A	WO 97 42187 A (LOHMANN JEAN JACQUES MARCEL ;PLE PATRICK (FR); HENNEQUIN LAURENT F) 13 November 1997 (1997-11-13) the whole document -----	1-20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 02/00947

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 8 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims 1-7 cover all potential diseases devined by a result to be achieved, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of diseases. Furthermore prodrug is a functional expression, i.e. the compounds are defined by a result to be achieved while the description seems to prodide support only for esters of compounds of formula (I) containing carboxy or hydroxy groups. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define a compound or disease by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the diseases mentioned in the description and for the esters of the compounds of formula (I).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 02/00947

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0156607	A	09-08-2001	AU 2886701 A WO 0156607 A1	14-08-2001 09-08-2001
JP 2000309534	A	07-11-2000	NONE	
EP 0673937	A	27-09-1995	AU 683492 B2 AU 7623794 A EP 0673937 A1 FI 952272 A KR 174752 B1 KR 188846 B1 NO 951813 A RU 2128648 C1 US 5721246 A US 5767283 A AU 711438 B2 AU 1778597 A CA 2146961 A1 CN 1114506 A , B HU 71551 A2 WO 9507276 A1 JP 7165708 A NZ 273073 A RU 2121997 C1	13-11-1997 27-03-1995 27-09-1995 06-07-1995 01-02-1999 01-06-1999 09-05-1995 10-04-1999 24-02-1998 16-06-1998 14-10-1999 14-08-1997 16-03-1995 03-01-1996 28-12-1995 16-03-1995 27-06-1995 25-09-1996 20-11-1998
US 4006161	A	01-02-1977	US 8427946 I5	23-03-1976
WO 9427963	A	08-12-1994	US 5521320 A AU 683052 B2 AU 6330694 A CA 2124430 A1 CN 1100094 A , B CZ 9401278 A3 EP 0700381 A1 FI 942422 A HU 72886 A2 IL 109796 A JP 2843759 B2 JP 6336476 A KR 220766 B1 NO 941967 A NZ 260587 A RU 2109013 C1 SG 55156 A1 WO 9427963 A1 US 5840915 A ZA 9403684 A	28-05-1996 30-10-1997 01-12-1994 28-11-1994 15-03-1995 15-12-1994 13-03-1996 28-11-1994 28-06-1996 17-08-1999 06-01-1999 06-12-1994 15-09-1999 28-11-1994 25-06-1996 20-04-1998 21-12-1998 08-12-1994 24-11-1998 25-01-1995
EP 0255178	A	03-02-1988	IT 1197804 B DE 255178 T1 EP 0255178 A2 GR 88300140 T1 JP 63099024 A	06-12-1988 30-06-1988 03-02-1988 16-12-1988 30-04-1988
EP 0008226	A	20-02-1980	AR 228019 A1 AR 226446 A1 AT 5188 T AU 526877 B2	14-01-1983 15-07-1982 15-11-1983 03-02-1983

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 02/00947

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
EP 0008226	A	AU 4946179 A	05-02-1981	
		CA 1127160 A1	06-07-1982	
		DE 2966364 D1	08-12-1983	
		DK 331679 A	09-02-1980	
		EP 0008226 A2	20-02-1980	
		ES 483252 A1	01-09-1980	
		ES 492954 D0	16-06-1981	
		ES 8105690 A1	01-09-1981	
		ES 492955 D0	01-07-1981	
		ES 8106482 A1	01-11-1981	
		GR 68102 A1	30-10-1981	
		HU 184114 B	30-07-1984	
		IE 48676 B1	17-04-1985	
		JP 1447038 C	30-06-1988	
		JP 55051041 A	14-04-1980	
		JP 62056861 B	27-11-1987	
		KR 8801067 B1	20-06-1988	
		KR 8801068 B1	20-06-1988	
		MX 5740 E	07-02-1984	
		PH 22340 A	12-08-1988	
		SU 1199197 A3	15-12-1985	
		SU 1053743 A3	07-11-1983	
		US 4472433 A	18-09-1984	
US 4472433	A	18-09-1984	AR 228019 A1	14-01-1983
			AR 226446 A1	15-07-1982
			AT 5188 T	15-11-1983
			AU 526877 B2	03-02-1983
			AU 4946179 A	05-02-1981
			CA 1127160 A1	06-07-1982
			DE 2966364 D1	08-12-1983
			DK 331679 A	09-02-1980
			EP 0008226 A2	20-02-1980
			ES 483252 A1	01-09-1980
			ES 492954 D0	16-06-1981
			ES 8105690 A1	01-09-1981
			ES 492955 D0	01-07-1981
			ES 8106482 A1	01-11-1981
			GR 68102 A1	30-10-1981
			HU 184114 B	30-07-1984
			IE 48676 B1	17-04-1985
			JP 1447038 C	30-06-1988
			JP 55051041 A	14-04-1980
			JP 62056861 B	27-11-1987
			KR 8801067 B1	20-06-1988
			KR 8801068 B1	20-06-1988
			MX 5740 E	07-02-1984
			PH 22340 A	12-08-1988
			SU 1199197 A3	15-12-1985
			SU 1053743 A3	07-11-1983
WO 0041669	A	20-07-2000	AU 1995700 A	01-08-2000
			EP 1140078 A2	10-10-2001
			WO 0041669 A2	20-07-2000
WO 9742187	A	13-11-1997	AU 2647597 A	26-11-1997
			EP 0912557 A1	06-05-1999
			WO 9742187 A1	13-11-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 02/00947

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9742187 A		JP 2000510115 T	08-08-2000
		US 6265411 B1	24-07-2001
		ZA 9703844 A	06-11-1997